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Chapter I 
Introduction 
Hypertension  
Hypertension is clinically defined as a condition in which blood pressure (BP) is persistently 
elevated above 130/90 mmHg (systolic/diastolic) [1]. Hypertension is a major healthcare problem 
and is a risk factor for myocardial infarction, stroke, renal and heart failure. Despite decades of 
studying this disease, the cause of most cases of adult hypertension remains unknown [2]. 
Perturbations of the kidney, vasculature, heart and central nervous system have been implicated 
in this disease. According to the new guidelines, 46% of the population in United States is 
hypertensive, and the occurrence of this disease increases with age. In 2010 and 2016, 
hypertension was ranked as the leading risk factor for global burden of disease in both developed 
and under-developed countries [1, 3]. Current treatments for hypertension include ACE 
inhibitors, β-blocking drugs, calcium-blocking drugs, and thiazide diuretics. In spite of our 
understanding of the renin/angiotensin system and the drugs available in the market, some 
people still have hypertension refractory to treatment. This indicates that the etiology of 
hypertension is still unknown, emphasizing the need to determine other mechanisms by which 
hypertension develops. Further, 90% of cases of hypertension do not have an identifiable 
etiology and are defined as “essential”. Essential hypertension in many cases co-exists with 
obesity, diabetes, other metabolic disorders and aging [4]. 
In the past several years, emerging evidence indicates that hypertension is an inflammatory 
process in which innate and adaptive immune cells infiltrate into the kidney, vasculature and the 
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brain. These cells secrete powerful mediators such as cytokines, chemokines and reactive 
oxygen species (ROS) that alter function of these organs, cause tissue damage and elevate BP. 
However, the precise mechanism in which this process occurs remains poorly understood. Blood 
pressure is the product of systemic vascular resistance and cardiac output and, thus, one of 
these must be elevated in chronic hypertension. Cardiac output is elevated early in hypertension 
and results in vascular adaptations including vasoconstriction, vascular remodeling and vascular 
rarefaction. These increase systemic vascular resistance and concomitantly normalize cardiac 
output. Guyton defined the concept of the “pressure-natriuresis” curve that determines a 
relationship between BP with sodium and water excretion [5]. There is a rightward shift in the 
relationship of BP with sodium and water retention that results in sustained hypertension. A 
change in the ability of the kidney to excrete water and sodium will result in an increase in mean 
arterial pressure. Enhanced reabsorption of sodium and water along the nephron is regulated 
through the activities of various proximal and distal sodium transporters. These include the 
sodium-hydrogen 3 exchanger (NHE3), the sodium-chloride cotransporter (NCC), the sodium-
potassium cotransporter (NKC), sodium-potassium chloride cotransporter (NKC2C) and the 
epithelial sodium channel (ENAC). Hypertension is associated with renal fibrosis, renal oxidative 
stress, glomerular injury and chronic kidney disease. Various hypertensive stimuli like 
angiotensin (Ang II), catecholamines, loss of nitric oxide and endothelin can increase sodium 
reuptake in the nephron, which is mediated by increased expression and activity of these 
transporters.  
In cases of sustained hypertension, vascular rarefaction within the kidney and fibrotic 
replacement of renal parenchymal tissue can occur, which results in defects of renal function. 
Vascular rarefaction is defined as loss of capillaries and resistance vessels [6]. Diuretic 
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treatment in hypertensive humans helps to normalize the pressure natriuresis curve. Guyton 
also proposed that an increase in cardiac output leads to systemic vasoconstriction, which 
further increases the BP. This vasoconstriction returns blood volume to near normal levels and 
promotes the pressure natriuresis. However, these sustained elevations of pressure lead to end-
organ damage commonly observed in hypertensive patients.  
Folkow et al. described a phenomenon in hypertension in which the vascular lumen is narrowed 
as the media thickens [6]. This remodeling process can reduce the cross-sectional area of 
resistance arterioles and thus increases systemic vascular resistance. Another phenomenon is 
aortic stiffening. The thoracic aorta serves a buffering function in which it accommodates a 
portion of the blood ejected from the heart during systole. During diastole, the aorta recoils and 
ejects blood into the periphery to the downstream circulation. This capacitance function of the 
aorta, also referred to as the “Windkessel” function, blunts systolic BP and maintains diastolic 
pressure and perfusion. In several diseases and aging, the aorta stiffens and the Windkessel 
function of the aorta is lost. The rapidity of the forward wave plus the increase in reflected waves 
raises systolic BP. Clinically, aortic stiffness can be estimated by measuring pulse wave velocity 
(PWV). Increased PWV is associated with diseases such as stroke, chronic kidney disease, 
heart failure and peripheral vascular disease [7, 8].  
The central nervous system also plays a crucial role in hypertension. Regions of the forebrain, 
the hypothalamus and the brain stem controlling the sympathetic and parasympathetic outflow 
and modulate vasoconstriction, vascular remodeling, vascular smooth muscle proliferation and 
increases cardiac output [9]. Sympathetic nerves innervate renal tubules, the juxtaglomerular 
granular (JG) cells of the kidney and renal vessels. Increased renal sympathetic nerve activity 
promotes an increase in sodium and water reabsorption in the nephron. Constriction of the renal 
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vasculature also stimulates renin release from JG cells in a feed-forward fashion that activates 
the renin-angiotensin (RAS) system [10]. Recent data indicate that renal sympathetic nerves can 
modulate activation and infiltration of innate and adaptive immune cells [11].    
Models of Hypertension 
Several rodent models are used to study hypertension. A common model involves Ang II infusion 
in mice or rats via osmotic mini pumps. These pumps are placed subcutaneously and release 
Ang II over the course of 7 to 28 days [12, 13]. Another commonly employed model of 
hypertension is the deoxycorticosterone acetate (DOCA)-salt model [14]. This results in a salt-
sensitive form of hypertension in which Ang II levels are markedly suppressed [15]. In the DOCA-
salt model, one kidney is removed, a pellet of DOCA is inserted subcutaneously and the animals 
are given excess sodium in their drinking water. DOCA is an aldosterone-like agent that 
increases sodium and water reabsorption in the kidney. Another model of hypertension involves 
administration of the nitric oxide synthase antagonist Nω-Nitro-L-arginine methyl ester 
hydrochloride (L-NAME). This raises systolic BP to about 140 mmHg [16]. A variant of this model, 
involves stopping L-NAME after a two to three week infusion. These animals then exhibit salt-
sensitivity in which adding salt to their diet increases their BP [17]. There are also genetic models 
of hypertension including the Dahl salt-sensitive (DSS) rats that were bred by Lewis K. Dahl [18]. 
These animals develop severe hypertension and renal damage when fed salt. There is another 
salt-resistant strain that is used as a control Dalh salt-resistant (DSR). Extensive research has 
employed inner crosses between these two strains to identify chromosomes that convey 
hypertension [19]. Of late, researchers have begun to manipulate the DSS rat using zinc-finger 
DNAse gene targeting [20]. Another model of hypertension is the spontaneously hypertensive 
rat (SHR). These rats were made by outbreeding Wistar Kyoto rats and selecting for animals 
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with higher blood pressures. A variant of these is called the SHR stroke-prone has severe 
hypertension and is predisposed to stroke [21]. Loft et al. created a double transgenic rat 
expressing the human angiotensinogen and renin genes. These rats develop hypertension and 
die of end-organ damage by 7 weeks of age [22]. Another model is the Schlager mouse, which 
have an increase in sympathetic nerve activity in hypertension [23]. There are advantages and 
disadvantages to these and other models of hypertension, but they exhibit similar phenotypes 
to humans with this disease. These models demonstrate left ventricular hypertrophy, renal 
damage, vascular dysfunction, and can develop stroke. The drugs used to treat human 
hypertension lower blood pressure in these various models. Advantages of rat models are that 
the animals are larger. The advantages of mice are that they are more easily genetically 
modified, and the murine immune system is much better characterized. Reagents needed to 
study the immune system are readily available for mice and not for rats.         
Oxidative stress in hypertensive disease  
It has become increasingly evident that ROS contribute to the development of hypertension. In 
addition, our laboratory and others have shown a role of ROS and immune activation during 
hypertension disease. ROS can be divided into two major groups: free radicals and non-radical 
derivatives. Free radicals possess an unpaired electron in their outer orbital making them highly 
reactive. Among these are superoxide (O2.-), the hydroxyl radical (OH.), lipid peroxy-radicals 
(LOO.) and alkoxy- radicals (LO.) [24]. Nitric oxide (NO) is also a free radical, and often referred 
to as a reactive nitrogen species. Non-radical ROS include hydrogen peroxide (H2O2), the 
Peroxynitrite anion (ONOO-), hypochlorous acid (HOCl-) and reactive carbonyls. These latter are 
more stable because they do not possess unpaired electrons and have a longer half-life, but 
maintain strong oxidant properties.     
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Although originally considered toxic by-products of cellular metabolism, ROS are now 
recognized to have signaling roles that are critical for normal cell function including proliferation, 
differentiation, aging, host-defense and repair processes [25]. Recent studies show that ROS, 
including H2O2, may drive pro-survival signaling and protection from the aging process [26]. As 
a part of innate immunity, phagocytes exhibit a respiratory burst in which they release large 
amounts of ROS to kill bacteria and other pathogens. This is accomplished by activation of the 
Nox-based nicotinamide adenosine dinucleotide phosphate (NADPH) oxidase discussed below. 
ROS also participate in tissue repair and remodeling by inducing expression of matrix 
metalloproteinases (MMPs) [27]. These vital responses for normal cell function and are 
exacerbated in disease states and promote pathological processes. The term oxidative stress 
refers to an imbalance between the production of ROS and antioxidant defenses [28]. 
Superoxide, produced by 1-electron reduction of molecular oxygen, can act both as an oxidant 
and as a reductant in biological systems, depending on the redox potential of the molecule with 
which it is reacting [29]. Superoxide is important because it serves as a progenitor for many 
other biologically relevant ROS, including H2O2, HO· and OONO-. The last of these forms upon 
reaction of O2·– with NO [30]. Hydrogen peroxide is formed by dismutation of O2·–, which can 
occur either spontaneously or can be catalyzed by the superoxide dismutases (SODs). In 
contrast to superoxide, H2O2 is relatively stable under physiological conditions. Because it is 
uncharged and lipophilic, H2O2 can readily diffuse across membranes and thus can react with 
targets in organelles and cells apart from where it is formed [24]. In this regard, H2O2 has been 
implicated as a signaling molecule that can, among other actions, promote vasodilatation, 
activate gene transcription, modify phosphatase activity and activate other sources of ROS [31]. 
As part of the antioxidant defense mechanisms, catalase and glutathione peroxidase (Gpx) can 
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reduce H2O2 to H2O. As mentioned above, OONO- is the product of the spontaneous reaction 
between O2.- and NO. This reaction is essentially diffusion limited, and its rate has been 
estimated to be 9 X 109 mols X sec-1, which is faster than that of the reaction of O2·– with the 
superoxide dismutases [32]. At physiological pH, OONO- exists in the protonated form, HOONO 
or peroxynitrous acid, which is uncharged and can diffuse across cell membranes. Peroxynitrite 
often reacts and modify proteins and other cellular structures causing oxidative damage to these 
molecules. In particular, OONO- modifies protein tyrosine residues to form 3-nitrotyrosine, a 
biomarker for OONO- in tissues and blood. 
The NADPH oxidases are major sources of ROS in mammalian cells, which play a role in host 
defense. The catalytic subunits of these enzyme complexes are the NOX proteins. Seven NOX 
proteins have been identified with differential tissue distribution, diverse function and regulation 
mechanisms. NOX1 is known to exist in colon, muscle, prostate, uterus and blood vessels and 
plays important roles in host defense and blood pressure regulation [33]. NOX2 is found in 
phagocytes, where it is responsible for the oxidative burst.  It is also present in endothelial cells 
and the tubular cells of the kidney [34]. NOX3 is present in fetal tissue and inner ear and is 
essential for vestibular function. NOX4, expressed in kidneys, vessels and bone, is involved in 
vasoregulation and erythropoietin synthesis. NOX5, not present in rodents, is a Ca2+-dependent 
homolog that produces O2.- in response to intracellular Ca2+ mobilization in lymph nodes, testes 
and blood vessels. NOX5 is also expressed in atherosclerotic lesions and seems to be higher in 
more complex lesions [35].  
The phagocytic NADPH oxidase is composed of membrane-bound and cytoplasmic 
components. The membrane components include the large glycosylated protein, gp91phox 
(NOX2), and a smaller adaptor protein p22phox which together compose the cytochrome b558 [36]. 
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NOX2 has two heme groups and binds to the redox cofactor flavin adenine dinucleotide (FAD) 
that is essential for the electron transfer. During NOX2 activation, the proline rich area in the C-
terminal region of p22phox functions as a docking unit for activated p47phox and can also bind 
p40phox [37, 38]. In addition to p47phox, other subunits located in the cytoplasm are required for 
NOX2 activation including p67phox and the small GTPase Rac2. Upon activation, these subunits 
translocate to the membrane components initiating electron transfer. The electron transfer 
occurs from NADPH to FAD and then to the heme groups; ultimately reducing molecular oxygen 
(O2) to produce superoxide [39].  
A major development in the past two decades has been the realization that NADPH oxidases 
exist in non-phagocytic cells. As mentioned above, NOX subunits are present in various vascular 
cells and can be activated by pathophysiological stimuli. As an example, Ang II activates the 
NADPH oxidases via the AT1 receptor and stimulation of a signaling pathway involving c-Src, 
protein kinase C (PKC), phospholipase D (PLD) and phospholipase A2 (PLA2) and activating 
Rac1 [40]. In addition Ang II increases vascular p22phox expression in vivo and deletion of this 
subunit in vascular smooth muscle cells (VSMCs) prevents ROS formation [41, 42]. The NADPH 
oxidases are also activated by a variety of physiological and pathophysiological stimuli, including 
inflammatory cytokines, growth factors, mechanical forces and various G protein coupled 
receptor agonists. Overexpression of VSMCs p22phox enhances hypertension and hypertrophy 
in response to Ang II [43]. In addition, we found that overexpression of p22phox in VSMCs of mice 
increases collagen deposition, aortic stiffness, renal dysfunction and hypertension with age [44]. 
Patients with chronic granulomatous disease lack subunits of the NADPH oxide and suffer from 
recurrent and life-threatening infections [45]. 
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The nitric oxide synthase (NOS) enzymes are the endogenous sources of NO in mammalian 
cells.  By producing NO, these enzymes have myriad effects on cardiovascular function, 
including modulation of vascular tone, blood pressure, sympathetic outflow, renal renin release 
and renal sodium excretion [46]. In the absence of their critical cofactor tetrahydrobiopterin 
(H4B), or their substrate L-arginine, the NOS enzymes become uncoupled, such that they 
produce O2.- rather than NO. NOS uncoupling has been documented as a source of ROS in 
diseases such as hypertension, atherosclerosis, diabetes and following ischemia and 
reperfusion injury [47]. Importantly, oral H4B blunts the elevation of BP in Ang II- and salt-induced 
hypertension in animals and has been shown to lower BP in humans with hypertension [47-49]. 
A major cause of NOS uncoupling is oxidation of H4B by oxidants such as peroxynitrite [50]. 
Interestingly, ROS produced by the NADPH oxidase play a role in this process, and mice lacking 
the NADPH oxidase are protected against H4B oxidation in the setting of hypertension [51].   
A large body of literature has shown that excessive production of ROS contributes to 
hypertension and that scavenging of ROS decreases BP.  In an initial study, Nakazono and 
colleagues showed that bolus administration of a modified form of SOD acutely lowered BP in 
hypertensive rats [52].  Our laboratory was among the first to show that membrane-targeted 
forms of SOD and SOD mimetics such as tempol lower blood pressure and decrease 
renovascular resistance in hypertensive animal models [53-55]. There is ample evidence 
suggesting that ROS not only contribute to hypertension but that the NADPH oxidase is their 
major source. Components of this enzyme system are up-regulated by hypertensive stimuli, and 
NADPH oxidase enzyme activity is increased by these same stimuli. Moreover, both Ang II-
induced hypertension and DOCA-salt hypertension are blunted in mice lacking components of 
the NADPH oxidase [56]. Hypertension is associated with increased ROS production by multiple 
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organs, including the brain, the vasculature, and the kidney, all of which are likely important. It 
is likely that all of these organs are important in the genesis of hypertension and that there is 
important interplay between these that causes this disease. Elevated vascular ROS promotes 
the development of hypertension in various animal models, including Ang II-induced, DOCA-salt 
hypertension [56-58], Dahl salt-sensitive hypertension and SHR rats [59-61].  
Humans with hypertension have alterations of vascular reactivity. The endothelium regulates 
vascular tone via release of endothelium-derived relaxing factors (EDRFs) and endothelium-
derived contractile factors (EDCFs). Oxidative stress causes imbalanced production and 
bioavailability of these molecules leading to endothelial dysfunction. NO is one of the most 
important mediators of endothelium-dependent relaxation in BP regulation. The major 
mechanism for alteration of NO bioavailability when superoxide is increased is that this radical 
reacts with NO at an extremely rapid rate, as discussed above.  Uncoupling of endothelial NOS 
(eNOS), due to deprivation of the cofactor H4B,results in reduced NO release, increased 
superoxide production, impaired endothelium-dependent relaxation and elevated arterial 
pressure [47, 48, 62]. Similarly, lack of eNOS substrate L-arginine also reduces NO 
bioavailability and impairs NO-induced dilation. L-arginine is the substrate for both eNOS and 
arginase, and increased arginase activity reduces the local bioavailability of L-arginine [63]. 
Interestingly, peroxinitrite and hydrogen peroxide have recently been shown to increase the 
expression and activity of arginase in endothelial cells, potentially contributing to endothelial 
dysfunction [64].    
Diverse stimuli common to the hypertensive milieu, including Ang II, aldosterone, 
catecholamines, increased vascular stretch, and endothelin promote ROS production, which 
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then increases expression of proinflammatory molecules that cause rolling, adhesion, and 
transmigration of inflammatory cells [65, 66].  
Innate Immunity  
The innate immune system is the first line of defense against invading pathogens such as 
microbes, viruses or fungi. The innate immune system is composed of physical and chemical 
barriers to prevent infection as well as the recognition of invading pathogens by various cell 
types. Initial barriers include the epidermis, vascular endothelium, respiratory epithelium and 
mucosal surfaces [67]. Cellular components include antigen presenting cells (APCs) such as 
dendritic cells (DCs) and monocytes, phagocytic macrophages and granulocytes, natural killer 
(NK) cells and innate lymphoid cells. The innate immune system is important in that it detects 
foreign microbes early during infection by recognizing evolutionarily conserved structures on 
pathogens called pathogen-associated molecular patterns (PAMPs) through germline-encoded 
pattern-recognition receptors (PRRs) and begins clearance by employment of complement 
activation, phagocytosis, and autophagy [68].  
PRRs on immune and nonimmune cells survey the extracellular and intracellular space for 
conserved microbial determinants that can indicate infection. Charles Janeway Jr. was the first 
to describe two features of innate immunity including the ability to distinguish self from non-self-
molecules and the ability of the innate immune system to activate the adaptive immune system 
[69]. Innate immunity relies on the release of local mediators and phagocytes, while the adaptive 
immune system uses antigen-specific T and B cells. Phagocytes are responsible for clearing 
pathogens mainly by phagocytosis, but also by the release of proinflammatory cytokines and 
chemokines that allow recruitment of other immune cells to the site [70]. Further, in response to 
pathogens, phagocytes such as neutrophils and macrophages release respiratory or oxidative 
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burst, which helps destroy the internalized pathogen [71]. The expression of PRRs on these 
cells allow them to detect specific pathogens and in a way gives a degree of specificity like the 
adaptive immune system [72]. PRRs are classified into five different families based on their 
protein domain homology including: Toll-like receptors (TLRs), C-type lectin receptors (CLRs), 
nucleotide-binging domain, leucine-rich repeat (LRR)-containing or NOD-like receptors (NLRs), 
RIG-I-like receptors (RLRs) and the AIM2-like receptors [73]. There are two main classes of 
PRR families, distinguished by their membrane-bound receptors or unbound intracellular 
receptors. Membrane-bound receptors include TLRs and CLRs that survey the presence of 
microbial ligands in the extracellular space or the endosomal space. NLRs, RLRs and ALRs are 
located within the cytoplasm and survey the presence of intracellular pathogens such as viruses 
[74]. PRR activation initiates either a transcriptional or a non-transcriptional innate immune 
response, which ultimately leads to adaptive immune responses. The production of 
proinflammatory cytokines and interferons (IFNs) in response to a PRR-induced response is a 
critical component for initiating innate and adaptive immune responses [75]. Other responses 
include phagocytosis, autophagy, cell death and cytokine processing, which are linked to the 
tightly controlled signal transduction pathways [76].  
TLRs are transmembrane glycoproteins that contain an extracellular domain, a transmembrane 
domain and an intracellular toll/interleukin-1 receptor (TIR) homology domain. The extracellular 
domain is essential for ligand recognition and has a horseshoe-like structure [77]. There are 13 
types of TLRs, three of which are not expressed in humans, and they are distinct for their ligand 
specificity. TLR4 was the first toll-like receptor to be identified [78]. Poltorak et al. showed that 
mice with selective mutations in the TLR4 gene that detects Lipopolysaccharide (LPS) are 
resistant to endotoxin but are highly susceptible Gram-negative sepsis [79]. Thus, TLR4 requires 
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a multi-receptor complex in response to LPS binding that consists of LPS-binding protein (LBP), 
CD14 and MD-2 in order to extract LPS from bacteria and initiate signaling. [80].  
Cluster of differentiation (CD) 14 is a membrane protein initially identified by its interaction with 
LPS and is expressed on myelomonocytic cells. CD14 displays a dimeric structure that 
resembles the TLR4 extracellular domain and can be released as a soluble factor or be a 
glycosylphosphatidylinositol (GPI)-anchored glycoprotein [81]. CD14 anchors to regions on the 
plasma membrane with high density of cholesterol called lipid rafts, which are essential regions 
for protein signaling, trafficking and endocytosis [82]. CD14 lacks an intracellular tail, however, 
with the aid of adaptive proteins it can initiate signaling that leads to calcium influx and gene 
regulation via nuclear factor of activated T cells (NFAT) activation independent of TLR4 signaling 
[83]. The proinflammatory signaling occurring in response to activated PRRs ultimately leads to 
activation, maturation and induction of the adaptive immune system. Major players in this 
signaling response include transcription factors NFκB, AP1 and IRF3/7 that stimulate the 
production of proinflammatory mediators such as cytokines and IFN [84]. Specifically, NFκB 
plays a central role in both innate and adaptive immunity by orchestrating the expression of 
multiple genes that are essential for an immune response. Many proinflammatory cytokines 
including IL-6, IL-1 and TNFα and chemokines such as RANTES and IL-8 can be induced in 
response to NFκB activity [85]. Further, many molecules involved in inflammation are 
upregulated in response to PRR activity and NFκB including cytokines, immunoreceptors and 
chemokine receptors, TLRs, major histocompatibility complex (MHC) molecules, costimulatory 
molecules and immunoglobulins [74]. All of these factors are essential for the activation and 
recruitment of leukocytes to sites of inflammation, enhanced phagocytosis and apoptosis by 
complement or NK cell-mediated lysis and enhanced antigen presentation.  
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Monocyte subsets and implications in disease 
Monocytes are a relatively large circulating leukocyte with a diameter of 12-20 µm that are part 
of the mononuclear phagocyte system [86]. Monocytes originate from myeloid common 
progenitor, which gives rise to monocyte precursors (MPs) that give rise to monocytes that are 
then released from the bone marrow [87, 88]. Human monocytes are sub-classified on their cell 
surface expression of CD14 and CD16, the Fcγ (III)-receptor. Classical monocytes express 
CD14 and little to no CD16 and comprise 90-92% of all monocytes. Non-classical monocytes 
express lower levels of CD14 and high levels of CD16. In 2010, another subset of monocytes 
expressing both CD14 and CD16 was identified and named intermediate monocytes [89]. 
Monocytes survive in circulation up to 72 hours and can migrate into the tissue to act as 
phagocytes, differentiate into a different subset of cells or die [90]. In humans, ten percent of all 
nucleated cells in blood are monocytes and they concentrate in specialized tissues including 
spleen and lungs and they can be mobilized from these sites to other tissues in response to 
pathological stimulus [91]. Once monocytes reach the designated tissue, they can produce 
effector molecules and phagocytose microorganisms, lipids, other toxic molecules, and cells 
undergoing apoptosis [92]. Effector molecules of monocytes that can initiate inflammation 
include cytokines, chemokines, ROS, MMPs, MHC, costimulatory molecules and other T cell 
interacting factors. 
Monocytes represent accessory cells that link the innate immune system with the adaptive 
immune system by acting as APCs to T cells to induce an immune response. Importantly, 
monocytes are heterogeneous and plastic cells that can serve as progenitors to different subset 
of cells including macrophages and DCs [93]. These latter two cell types can present antigen to 
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T cells. Recently, it has been recognized that monocytes can be activated to present antigen 
with minimal differentiation [94].   
Monocytes have both beneficial and deleterious properties. Monocytes can clear antigen and 
generate a beneficial immune response when needed. However, they have detrimental effects 
when their activity is prolonged that can ultimately lead to end-organ damage. Monocytes play 
an important role in inflammation and are increased in the circulation and activated in many 
inflammatory diseases including different types of cancers, atherosclerosis, and coronary artery 
disease (CAD) [92, 95, 96]. Classical monocytes express a wide range of genes associated with 
the process of phagocytosis including CD64, CD14, and CD93. Additionally, classical monocytes 
have the highest expression of antimicrobial proteins making this subset one of the first lines of 
innate immunity [97]. Previous studies have indicated that loss of monocytes prevents 
development of vascular dysfunction and oxidative stress in atherosclerosis [98] and 
hypertension [99]. Recent studies using deuterium labeling have shown that intermediate and 
non-classical monocytes arise sequentially from the classical population. The circulating lifespan 
of intermediate and non-classical monocytes (4 and 7 days, respectively) is much longer than 
classical monocytes (1 day) [100]. In culture, classical monocytes acquire increasing levels of 
CD16 with time [101]. Classical monocytes can differentiate into various subtypes of monocytes, 
DCs or macrophages in response to stimulus such as growth factors, cytokines, and immune 
responses. 
Non-classical monocytes (CD14lowCD16++) have high levels of TNFα and IL-1β in response to 
LPS. In addition, non-classical monocytes have the highest expression of CX3CR1 and genes 
necessary for adhesion including integrin α [97], the integrin-associated protein CD47, 
sialophorin (CD43)-a ligand for ICAM-1, and PECAM-1, which triggers endothelial adhesion and 
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integrin-mediated migration to tissue [102]. Studies by Urbanski et al. have shown that the 
presence of non-classical monocytes corresponds with reduced vascular responses to 
acetylcholine, indicative of impaired endothelial function in patients with CAD [96]. Non-classical 
monocytes have been associated with increased body mass index (BMI) and carotid intimal 
medial thickening, a marker of early atherosclerosis in patients at low risk for cardiovascular 
diseases [103]. The number of circulating non-classical monocytes correlates with subclinical 
atherosclerosis in patients with systemic lupus erythematosus [104]. In addition, in patients with 
endothelial dysfunction non-classical monocytes exhibit high expression of CD11c, suggesting 
an increase in activation [96]. Also in this study, non-classical monocytes correlated with 
superoxide production of vessels removed from patients. Conversely, other studies have shown 
that the non-classical monocytes patrol capillaries after adoptive transfer, do not produce ROS 
and are weak producers of inflammatory cytokines after exposure to LPS or TLR1/TLR2 agonists 
[105]. These cells produce IL-1β and CCL3 in response to viruses and immune complexes via 
MyD88-MEK pathway [105].  
In 1989, Passlick et al. described a new subset of blood monocytes characterized by the co-
expression of CD14 and CD16 [101]. These were named intermediate monocytes 
(CD14++CD16+) and were found to comprise of approximately 2.2% of the mononuclear cells. 
Intermediate monocytes have been implicated in inflammatory diseases including Kawasaki 
disease [106], psoriasis [107] rheumatoid arthritis [108], sepsis [109], HIV [110], acute heart 
failure [111], and coronary artery disease [111]. Dialysis patients without infection have an 
increase in the number of circulating intermediate monocytes and those suffering from chronic 
infection have higher levels of these cells compared to healthy controls. In addition, intermediate 
monocytes express higher levels of MHC class II antigens including histocompatibility leukocyte 
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antigen (HLA)-DR,DP and –DQ compared to other monocyte subsets [112]. Intermediate 
monocytes also exhibit enhanced phagocytosis and produce high levels of ROS [97] and 
inflammatory mediators such as TNFα [113] and IL-1β [114]. Intermediate monocytes have 
higher levels of soluble ICAM-1 and, similar to non-classical monocytes, high levels of CD11a 
and CD11c [106], which bind to ICAM-1 on the endothelial cells promoting adhesion and 
migration into tissues [115] [116]. Rossol et al. showed that intermediate monocytes produce 
high levels of TNFα upon co-culture with pre-stimulated CD3+ T cells from healthy individuals. 
Intermediate monocytes also have the highest expression of CCR5, CD68 and lower ABCA1 
expression than classical monocytes in chronic kidney disease patients [117]. The ligand for 
CCR5, CCL5 or RANTES, is expressed in atherosclerotic plaques and genetic deletion of CCR5 
protects against experimental atherogenesis suggesting a potential role of intermediate 
monocytes in atherosclerosis [118]. Further, intermediate monocytes take up oxidized low-
density lipoprotein cholesterol, known to promote experimental atherosclerosis [117]. In addition, 
intermediate monocytes from dialysis patients have a high expression of membrane-bound 
angiotensin converting enzyme (ACE), the enzyme that converts Ang I to Ang II [119]. 
Intermediate monocytes have been shown to independently predict cardiovascular events in 
subjects referred for elective coronary angiography [120]. Classical, intermediate and non-
classical monocytes are defined by their expression of different markers in mice and humans 
and these are summarized in Table 1-1 [121].  
Calzada-Wack and colleagues found that blood monocytes spontaneously undergo maturation 
in culture and this is evident by the decrease in expression of CD33, a myelomonocytic stem 
cell marker [122]. This group found that addition of IL-10 to these monocytes in culture further 
reduced the expression of CD33 and gained the expression of CD16. In addition, Eligini et al. 
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showed similar results in that human monocytes spontaneously differentiate into macrophage 
after 7 days in autologous serum and that these cells have an overexpression of CD163, IL-10, 
TGFβ-2 and higher lipid content [123]. Thus, monocytes can have both beneficial and 
deleterious effects. 
Table 1-1. Human vs mouse monocyte subset of cells and their markers. 
 
 
Immune system in hypertension 
As early as 1954, Heptinstall described the presence of lymphocytes in kidneys of humans with 
hypertension [124]. In the 1960s, Okuda and Grollman showed that transfer of lymphocytes from 
rats with unilateral renal infarction transferred hypertension to recipient rats. In 1972, Olsen 
described an inflammatory reaction adjacent to the small arteries and arterioles of humans with 
hypertension consisting of T cells and monocytic cell [10]. In the 1970s, Svendsen discovered 
mice that were thymectomized do not maintain hypertension after renal infarction. In the last 12 
years, there has been a reemerging interest in the role of the immune system in hypertension. 
In the early 2000s, our group showed that recombination-activating gene 1 (RAG1-/-)-deficient 
mice, which lack both T and B cells, are protected against Ang II-induced and DOCA-salt 
hypertension and maintain vascular endothelial function [125]. Adoptive transfer of T cells, but 
not B cells, restored the hypertensive response and vascular dysfunction similar to wildtype (WT) 
mice. In addition, the deletion of RAG1 gene in Dahl-salt-sensitive rats attenuated hypertension 
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and renal damage upon high-salt feeding, again showing the role of adaptive immunity in the 
development of hypertension [20]. Crowley et al. showed that mice deficient in lymphocytes or 
SCID mice are also protected against high blood pressure and cardiac hypertrophy during Ang 
II-induced hypertension [126].  
Several studies address the types of T cells involved in hypertension. Specifically, our laboratory 
found that CD8+ T cells and not CD4+ T cells play a crucial role in this disease. Mice lacking CD8 
(CD8-/-) and OT1xRAG1-/-, which only have one T cell receptor, were protected against Ang II-
induced hypertension; while, mice lacking CD4 and MHCII were not [127]. Adoptive transfer of 
CD8+ T cells but not CD4+ T cells restored the hypertensive phenotype in RAG1-/- mice. Youn et 
al. examined circulating T lymphocytes in hypertensive patients and age- and sex-matched non-
hypertensives. They found an increase number in senescent circulating CD8+ T cells in humans 
with hypertension [128].   
There is also evidence that CD4+ T cells are activated in hypertension. An important cytokine 
seems to be interleukin 17a (IL-17A). Mice lacking IL-17A, a cytokine largely produced by CD4+ 
T cells, are protected against Ang II-induced hypertension, and infusion of the soluble IL-17C 
receptor lowers blood pressure and prevents oxidative stress in rats with experimental pre-
eclampsia [129, 130]. IL-17A raises blood pressure when administered to normal mice and it 
can induce phosphorylation of eNOS at threonine 495, which is an inhibitory site that leads to 
impaired endothelium-dependent vasodilation [131]. Our groups also found that IL-17A 
production is increased in circulating CD4+ T cells of humans with hypertension [132]. In addition, 
our group found that effector memory T cells accumulate in the kidney and bone marrow in 
response to L-NAME/high salt or repeated Ang II stimulation in mice [17]. This increase in 
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effector memory T cells is associated with an increase in the surface expression of the 
costimulatory molecule CD70 by antigen presenting cells such as macrophages and monocytes. 
CD70 is a costimulatory factor that reacts with CD27 on T cells and is important for formation of 
memory T cells. Mice lacking CD70 were protected against repeated hypertensive challenges. 
Another T lymphocyte subset, the T regulatory (reg) cells, have immune suppressant roles and 
have been shown to lower BP in Ang II-induced hypertension. Adoptive transfer of T cells from 
Scurfy mice, which lack T reg cells, to RAG1-/- mice worsen microvascular remodeling and 
stiffening in Ang II-induced hypertension [133]. Another cell type from the adaptive immune 
system that plays a role in hypertension is the B cell. Previous research in preeclampsia, an 
illness that affects 2-8% of pregnancies, has shown the presence of circulating autoantibodies 
against the angiotensin AT1 receptor [134]. These antibodies are agonistic such that when they 
bind to the AT1 receptor they promote vasoconstriction and renal sodium retention. Further, B 
cell-activating factor receptor deficient mice (BAFF-R-/- mice), which lack mature B cells, have 
blunted systolic blood pressure in response to Ang II as well as a reduction of the initial increase 
in circulating IgG observed in WT mice [135].  
The innate immune system also plays an essential role in the development of hypertension. De 
Ciuceis et al. performed studies in Op/Op mice, which are deficient in the macrophage colony-
stimulating factor and therefore cannot form these cells, and showed that these mice are 
protected against Ang II-induced hypertension [136]. Wenzel et al. showed that depletion of 
lysozyme M-positive (LysM+) myelomonocytic cells by diphtheria toxin attenuated Ang II-induced 
hypertension, vascular endothelial dysfunction and reduced vascular superoxide formation [99]. 
This group further found that adoptive transfer of WT CD11b+Gr-1+ monocytes to depleted LysM+ 
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mice reestablished the Ang II-induced hypertension, vascular dysfunction and oxidative stress 
confirming an important role of monocytes in the development of hypertension.  
 
 
Figure 1-1: The role of dendritic cells in hypertension. Hypertension induces production of reactive 
oxygen species in dendritic cells, leading to oxidation of arachidonic acid and formation of isolevuglandins 
(IsoLG). IsoLGs rapidly ligate to protein lysines in the dendritic cell, forming proteins that are recognized 
as non-self. Peptides from these are presented to T cells, leading to T cell proliferation. IsoLG formation 
also promotes DC production of cytokines including IL-1β, IL-6 and IL-23, which polarize T cells to 
produce specific cytokines. Adapted from McMaster et al. [137] 
 
 
Our laboratory also showed a link between the adaptive and innate immune system in which the 
B7 ligands that include CD80 and CD86 on antigen presenting cells are essential for the 
development of hypertension [138]. The B7 ligands interact with the T cell co-receptor CD28, in 
turn, promoting T cell activation. We showed that blocking the B7 ligands with CTLA4-Ig reduced 
both Ang II and DOCA-salt induced hypertension. We showed that mice lacking the B7 ligands 
are protected against hypertension and this protection is lost after transplant of WT bone marrow. 
Dendritic cells (DCs) are another cell type from the innate immune system that our group and 
others have found to be important in hypertension. In a study that I participated in, we found that 
DCs from Ang II-induced hypertensive WT mice have increased amounts of ROS and 
accumulate isolevuglandin (IsoLG) protein adducts [139]. Compared to macrophages and other 
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DC subsets, the myeloid or monocyte derived DCs had the highest accumulation of these IsoLG-
adducts in hypertensive mice suggesting a potential role of monocytes in differentiation and 
activation in this disease. The formation of these IsoLG-adducts corresponds to the production 
of IL-6, IL-1β and IL-23. Further, these modified proteins in DCs seem to act as neoantigens that 
promote T cell proliferation and production of cytokines including IL-17 and IFN-γ. A schematic 
of the main findings in this study are illustrated in Figure 1-1. Transfer of DCs from a hypertensive 
mouse primes hypertension in recipients in response to low dose of Ang II. I showed that 
exposure of DCs from WT mice with prooxidant tert-butyl hydroperoxide (t-BHP) promotes 
formation of IsoLG-adducts in the myeloid-derived DC populations, which in turn can promote 
CD8+ T cell proliferation. Adoptive transfer of t-BHP-treated DCs to WT mice exposed to a 
subpressor dose of Ang II leads to a hypertensive response in these mice (Figure 1-2). 
In another study that I participated in, we found that a major stimulus for IsoLG-adduct formation 
is sympathetic nerve activity, and in particular, renal sympathetic nerves. While controversial, 
renal sympathectomy has been used to treat hypertension. We sought to determine if renal 
sympathectomy would prevent immune activation in hypertension. We performed bilateral renal 
denervation using phenol and shows that this markedly reduced IsoLG-adducts formation in 
DCs, not only in the kidney, but also in the spleen [140]. As part of this paper, we showed that 
stimulation of DCs with norepinephrine promoted formation of IsoLG-adducts in these cells. 
Thus, a factor present in the hypertensive milieu that can cause immune activation is increased 
catecholamines. Immune cells possess adrenergic receptors and can be activated by 
innervation not only the kidney, but also the spleen and lymph nodes [141] [142]. The source of 
peripheral sympathetic activity originates from the central nervous system. We addressed this 
by using CRE-lox technology to delete the NADPH oxidase subunit p22phox in the subfornical 
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organ (SFO). This reduced sympathetic nerve activity, markedly blunted the hypertensive 
response to Ang II, prevented vascular inflammation and reduced T cell activation [143]. We 
also performed anteroventricular third ventricle (AV3v) lesions in mice and showed that this had 
a similar effect [144]. In contrast, we increased sympathetic outflow by deleting a key anti-oxidant 
from the subfornical organ (ECSOD) using CRE-lox technology and showed that this enhanced 
hypertension and T cell activation [145]. In keeping with these findings, Carnevale et al. showed 
that sympathetic enervation of the spleen showed placental-like growth (PlGF) production [146]. 
These data provide strong evidence that the central nervous system plays a central role in 
immune activation in hypertension. 
 
 
 
 
 
 
 
 
 
 
 
24 
 
 
Figure 1-2: Transfer of hypertension by dendritic cells. A. DCs were obtained from WT mice and 
treated with 1 mM t-BHP. One million of these treated DCs were adoptively transferred to recipient WT 
mice and blood pressure was monitored using telemetry. B. Systolic blood pressure in response to low-
dose Ang II infusion (140 ng/kg/min) 10 days after DC adoptive transfer. C. DCs were treated with 1 mM 
t-BHP and IsoLG-adducts were measured by flow cytometry using Alexa Fluor 488-tagged D11 antibody 
in CD11b+CD11c-, (D) CD11b+CD11c+ and (E) CD11b-CD11c+ cells. F. Expression of CD86 in DCs. G. 
Co-culture of t-BHP-treated DCs with T cells promoted survival of CD8+ T cells (n = 4-7, *p<0.05, ** 
p<0.01, *** p<0.001). Adapted from Kirabo et al. [139].  
 
 
Another stimulus of immune activation in hypertension is increased sodium. Hypertensive 
animals and humans have interstitial tissue concentrations of sodium that can exceed the blood 
plasma concentration by 40 mmol/liter [147]. These concentrations of sodium can stimulate IL-
17A production by T cells through the salt-sensing kinase serum and glucocorticoid-related 
kinase 1 (SGK1) [148]. We have found that deletion of T cell SGK1 blunts hypertension and 
reduces end-organ damage in response to Ang II or DOCA-salt [13]. I participated in a study in 
which we found that exposure of DCs to elevated sodium concentrations similar to that observed 
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in hypertensive humans increases formation of ROS and IsoLG-adducts in DCs [149]. We found 
that sodium enters DCs via an amiloride-sensitive channel and that this ultimately leads to 
activation of the NADPH oxidase. Further, these DCs exposed to high levels of sodium can 
stimulate T cells to proliferate and to produce IL-17A as well as transfer hypertension to a naïve 
recipient mouse exposed to the subpressor dose of Ang II.  
As discussed above, the kidney plays an essential role in the genesis of hypertension. 
Accumulating evidence supports a role of immune activation in renal dysfunction in this disease. 
Mice that lack the ability to produce IFN-γ and IL-17 are protected against activation of the 
sodium transporters described above [150]. Norlander et al. showed that IL-17 treatment of distal 
convoluted tubular cells caused phosphorylation of SGK1, which can in turn regulate ENAC [13]. 
Zhang et al. showed that mice lacking the IL-1 receptor 1 are protected against Ang II 
hypertension and this is associated with a reduction of the NKCC2 [151]. INF-γ released by 
adjacent T cells can stimulate angiotensinogen production by proximal tubular cells, thus, 
allowing formation of intrarenal Ang II further enhancing sodium reabsorption [152]. Multi 
genome-wide association studies identified a polymorphism in the Sh2b3 gene that encodes the 
adaptor protein LNK, which correlates to cardiovascular diseases including hypertension as well 
as other autoimmune disorders. Saleh et al. found that mice lacking LNK have higher 
inflammation in the kidney and vessels at baseline and that this is further exacerbated with Ang 
II infusion [153]. LNK deficient mice also develop exaggerated hypertension, ROS production, 
albuminuria and increased sodium and water retention in response to Ang II infusion. Thus, 
these animals that have an exaggerated immune response exhibit markedly renal damage and 
hypertension [154-156].   
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Recently it has been recognized that the gut microbiome is altered in hypertension that can lead 
to end-organ damage. Karbach et al. found that germ-free mice were protected against Ang II 
hypertension and had lower renal and vascular leukocyte infiltration compared to normal mice 
[157]. This reduction in leukocyte infiltration was associated with a reduction in mRNA 
expression of monocyte chemoattractant peptide 1 (MCP-1) and reduced endothelial leukocyte 
rolling. Further, germ-free mice had a reduction in cardiac infiltration of monocytes. More 
recently, Wilck et al. found that a 14-day challenge with high salt diet increased blood pressure 
and circulating IL-17A/TNFα positive T cells in humans and that this is associated with a 
reduction of fecal Lactobacilus species [158]. These data confirm an essential role of the immune 
system in hypertension as well as the interplay between various organs linked by both innate 
and adaptive immunity.      
Leukocyte recruitment to the vascular endothelium 
The process of leukocyte recruitment to the site of inflammation involves interaction with the 
vascular endothelium via a series of complex mechanisms that involves the activity of integrins, 
selectins and their ligands that initiate the capture and rolling of immune cells. In addition, 
chemokines released by vascular cells and resident immune cells further promote the 
transmigration of the adherent cells. ICAM-1 and VCAM-1 that are expressed by endothelial 
cells binds to lymphocyte function-associated antigen 1 (LFA1) and very late antigen 4 (VLA4), 
respectively, to allow the process of leukocyte rolling, a process that is triggered by cytokines 
and chemokines [159, 160]. Another integrin CD11b/CD18 integrin (MAC1) plays an important 
role in both neutrophil and monocyte crawling during inflammation [161]. The binding of integrins 
on leukocytes to endothelial cell receptors initiates a signaling event that begins through the 
activation of phospholipase C (PLC), activation of GTPases and integrin conformational changes 
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that allow the process of adhesion and transmigration to continue [162]. The process of crawling 
is the last step before leukocytes undergo transmigration. This process involves the binding of 
integrins such as MAC1 to endothelial cell molecules like ICAM-1 [163]. Leukocyte 
transmigration through the endothelial cell barrier occurs at a rapid rate (<2-5 minutes). 
However, leukocytes take longer to penetrate the endothelial cell basement membrane (>5-15 
minutes) [162]. This process can be facilitated or delayed according to the composition of the 
endothelial cell basement membrane, which is composed in part of pericytes. Leukocytes 
adherent to the endothelium can induce the formation of docking structures on the endothelium, 
which are projections rich in ICAM-1 and VCAM-1 [164]. In addition, platelet/endothelial-cell 
adhesion molecule-1 (PECAM-1) and junctional adhesion molecule A (JAM-A) exist at 
endothelial cell interphases and creates an adhesive gradient that helps promote transmigration 
[165]. The transmigration of leukocytes is a process that is stabilized by actin and vimentin [166]. 
Randolph et al. has shown that human monocytes can become DCs when they reverse-
transmigrate an endothelium that is stimulated with LPS, IL-1β, and zymosan [167]. Monocytes 
that remain in the subendothelium become macrophages. A schematic from a previous review 
article [162] of the process of leukocyte recruitment to the endothelium, the rolling and 
transmigration is illustrated in Figure 1-3.   
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Figure 1-3: The process of leukocyte transmigration through the endothelium. Adapted from Ley 
et al. [162]. 
 
Vascular endothelium and mechanical stretch in disease 
Vascular endothelial cells are subjected to various hemodynamic forces including mechanical 
stretch and shear stress that occur in response to the nature of blood flow. Under physiological 
conditions, these hemodynamic forces play an important role in modulating vascular 
homeostasis, cell structure, vascular angiogenesis, proliferation and vascular tone. 
Hypertension leads to excessive or high levels of mechanical stretch on vessels that lead to 
pathological consequences including formation of ROS, production of pro-inflammatory factors 
and lead to apoptosis [168]. Mechanical stretch is modeled in vivo through regulation of stretch 
intensity by the percent of cell elongation from the cell’s original dimensions. A low magnitude 
or elongation of stretch that is considered physiological ranges from 5%-10%, while high 
elongation pathological levels of stretch range from 10% and above and these are proposed to 
occur in hypertension [169]. Blood vessels are composed of different layers including the tunica 
intima, the tunica media and the tunica adventitia. The innermost tunica intima is the layer that 
contains the endothelial cells, the tunica media contains elastin, collagen and smooth muscle 
cells, and the outermost layer is the tunica adventitia that is composed of connective tissue, 
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collagen and elastic fibers. Blood vessels are exposed to two types of stresses in response to 
the pumping motion of the heart that includes sheer stress and mechanical stretch. Shear stress 
is the tangential drag of blood over the surface of the endothelium, while mechanical stretch is 
the longitudinal and circumferential deformation caused by elevations of distending pressure 
throughout the cardiac cycle.  
Mechanical stretch on vessels initiates a series of biochemical signaling cascades that begin 
from mechanoreceptors on the plasma membrane and ultimately lead to gene expression and 
protein synthesis that promote angiogenesis, proliferation, inflammation, apoptosis, vascular 
tone and cell survival. Three known mechanoreceptor proteins that detect mechanical stretch 
are stretch activated (SA) channel, integrin proteins and PECAM-1 [170]. The membrane-bound 
SA channel participates in calcium influx in response to stretch, which initiates PI3K and Rho-
associated kinase (ROCK) activation that is involved in cellular orientation [171]. Integrins 
transmit stretch signals from the extracellular matrix (ECM) into the cell and human umbilical 
vein endothelial cells (HUVECs) exposed to stretch express high levels on integrin αVβ3 through 
PI3K activation, which suggests an increase adhesiveness of the cells to RGD (tripeptide of L-
arginine, glycine, and –aspartic acid)-containing ECM substrates [172]. Further, the ECM 
contains a mixture of molecules including collagen, elastin, laminin and fibronectin among others 
that provides a structural support, adhesion sites, and is essential for vascular remodeling and 
homeostasis. PECAM-1 also known as CD31, is a cell adhesion molecule highly expressed in 
regions of cell-cell contact that can sense the change in cell morphology and induce MAP and 
extracellular signal-regulated kinase (ERK) 1/2 signaling leading to cellular reorientation [173].  
Endothelial cells develop morphological changes in response to mechanical stretch that occur 
due to cytoskeleton and focal adhesion complexes and in response to the emergence of stress 
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fibers, a bundle of 10-30 actin filaments [174]. Under static conditions, endothelial cells have a 
polygonal shape and random orientation. Endothelial cells become elongated and 
perpendicularly aligned in response to the stretch [168]. The ECM plays a role in physiological 
and pathological stretch in the vasculature. The synthesis and degradation of the ECM is 
essential for the process of vascular remodeling and for homeostasis of the tissue. MMPs 
produce zinc-dependent endopeptidases that can breakdown the ECM [175]. During normal 
levels of stretch, bovine arterial endothelial cells (BAEC) express MMP-2, while in pathological 
stretch levels HUVECs express increased levels of MMP-2 and MMP-14 and is mediated 
through TNFα and c-Jun amino-terminal kinases (JNK) pathways [176, 177]. Further, 
physiological stretch upregulates key tyrosine kinase receptors like FLT-1, Tie-2 and Tie-1 in 
HUVECs, which are genes involved in angiogenesis and the formation of new blood vessels 
[178]. Physiological stretch in BAECs induces cell proliferation by PI3K-dependent mammalian 
target of rapamycin (mTOR) pathway, which regulates cell cycle, proliferation and growth. 
Uncontrolled proliferation of endothelial cells that occurs in response to pathological stretch can 
lead to intimal thickening that increases vascular resistance and BP leading to vascular disease 
[179].       
Endothelial cell activation in response to mechanical stretch and other stimuli has long term 
effects including changes in mRNA and protein expression. Among the genes altered by stretch 
are cytokines, ROS producing-enzymes, adhesion molecules and MMPs. Further, 10% levels of 
cyclical stretch on human aortic endothelial cells (HAECs) lead to superoxide production, 
mediated initially by the NADPH oxidase and subsequently by the NO synthase depending on 
the presence of tetrahydrobiopterin compared to endothelial cells in static cultures [180]. 
Superoxide can be dismutated to H2O2 either spontaneously or via the enzymatic action of the 
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superoxide dismutases. ROS formation can in turn activate NFκB and transcription of adhesion 
molecules. Excess production of ROS or their impaired removal regulates many of the 
endothelial responses in a pro-inflammatory environment including monocyte adhesion and 
impaired endothelium-dependent relaxation. NO is a vasodilator that has anti-atherogenic 
properties and inhibition of NO results in severe hypertension and renal vasoconstriction [181]. 
Under physiological levels of stretch, endothelial cells increase NO release and reduce ROS 
formation having a “vasoprotective” effect [182]. Pathological or hypertensive levels of stretch 
can phosphorylate p66Shc in HAECs, which is an adaptor protein that increases superoxide anion 
formation that reacts with NO to generate ONOO- [183-185]. This mechanism will then reduce 
NO bioavailability that in turn contributes to endothelial dysfunction during hypertensive levels 
of stretch [186].     
 Immune cells from the innate and adaptive immune system accumulate in the blood vessel 
within the perivascular fat and adventitia during cardiovascular disease. These cells 
communicate with the vessel wall and can promote a series of events that ultimately lead to 
infiltration and activation of immune cells and the endothelium. Humoral or mechanical stimuli 
on endothelial cells can activate the NADPH oxidase and initiate signals that cause lymphocyte 
infiltration and T cell homing [154]. The cytokines released by T cells diffuse to vascular cells 
promoting further NADPH oxidase activation and, thus, ROS formation, as well as activation of 
MMPs in the endothelium and vascular smooth muscle cells. The chemokine RANTES, which is 
released by the endothelium, is detected by its receptor CCR5, that is expressed on T cells and 
in turn, initiates the process of infiltration. Inflammatory cytokines can also lead to reduction of 
NO, collagen synthesis and recruitment of more inflammatory cells [137]. We have shown that 
treatment of mice with etanercept, a TNFα antagonist, increases vascular ROS and enhances 
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endothelium-dependent vasodilation in Ang II-induced hypertension [125]. Vascular fibrosis 
occurs in response to vascular inflammation in hypertension. Hypertension increases cyclic 
stretch in large vessels and as proximal vasculature stiffens this increases the PWV to the distal 
vasculature and further enhances the end-organ damage. This stretch increases endothelial 
production and release of IL-6, IL-8, endothelin, ROS and other proinflammatory mediators 
[168]. Further increased endothelial stretch increases the expression of VCAM-1, ICAM-1 and 
CD40. We found that RAG1-/- mice and IL-17A-/- mice exposed to Ang II hypertension are 
protected against aortic stiffness [7]. Further, IL-17A produced by CD4+ T cells and γδ T cells 
play an important role in vascular dysfunction that occurs in response to hypertension [187]. We 
have shown that increased in endothelial cyclical stretch promotes monocyte activation and 
differentiation to its various proinflammatory subsets. This will be discussed in more detail on 
Chapter II.   
Signal transducer and activator of transcription and its implications in disease 
Signal Transducer and Activator of Transcription (STAT) are a family of cytoplasmic transcription 
factors that mediate intracellular signaling generated from the cell membrane to the nucleus and 
control many physiological processes and are exacerbated during inflammatory state [188]. In 
mammals, the STAT family has seven members including STAT1, 2, 3, 4, 5A and 6 and their 
structure is composed of six conserved domains. STATs structural domains have a helical N-
terminal, a coiled-coil four helix bundle, a central Ig-like DNA-binding domain, a helical liker, a 
Src-homology 2 (SH2) domain and a C-terminal transactivation domain [189]. STAT activation 
occurs by phosphorylation of a critical tyrosine residue located in the SH2 domain and C-terminal 
transactivation domain [STAT1 (Y701), STAT2 (Y690) and STAT3 (Y705)]. Upon cytokine 
stimulation, Janus kinases (JAKs) are recruited to the receptor and is phosphorylated at specific 
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residues that constitute docking sites for STAT monomers. Following this, STATs are recruited 
to the receptor via their SH2 domain and are phosphorylated by JAKs on the respective residues 
[190]. This phosphorylation enables STATs to either homodimerize or heterodimerize via their 
SH2 domains and translocate to the nucleus and interact with DNA motifs to promote gene 
transcription [191]. In STAT3, a second phosphorylation occurs at a single serine 727 that in 
some cases is necessary for maximal transcriptional activity of STAT3, but is not necessary for 
DNA binding [192-194]. In particular, STAT3 phosphorylation in the S727 occurs in response to 
members of mitogen activated protein kinases (MAPK) and JNK family of serine kinases [195].  
The entire STAT family can be divided into two groups; the first comprises of STAT2, STAT4 
and STAT6 that are involved in T cell development and IFN-γ signaling and the second 
comprises of STAT1, STAT3 and STAT5, which are also involved in IFN-γ signaling, 
development of mammary glands and embryogenesis [188]. In response to IL-6, IFN-α/β and 
IFN-γ activation STAT1 or STAT3 can form homodimers or heterodimers, which then promote 
expression of many genes. STAT1 and STAT2 are considered pro-inflammatory, while STAT3 
has pro-inflammatory and anti-inflammatory properties [189]. STAT3 and NFκB are constitutively 
active in many human tumors and they cooperate to induce the expression of many genes 
including CCL5, IL-1β, IL-6, IL-21, IL-17, P2, ICAM-1 and nitric oxide synthase [196].  
STATs play an important role in cardiovascular diseases. STAT1 is important for foam-cell 
formation, atherosclerotic lesion development, promotion of oxidative stress and neointimal 
hyperplasia [197, 198]. STAT1 activation in DCs is required for induction of MHC and co-
stimulatory molecules and, thus, antigen presentation and cross-presentation to activate CD8+ 
T cells [199, 200]. STAT1-depleted DCs have impaired regulation of MHC and costimulatory 
molecules as well as reduced Th1 cell priming in responses to Leishmania major [201]. STAT2 
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is involved in regulation of type I IFN signaling and gene expression [202], while STAT3 is 
involved in vascular SMC de-differentiation, lesion formation and recruitment of inflammatory 
cells to vessel wall in cardiovascular diseases [203]. In particular, STAT3 is involved in many 
oncogenic signaling pathways and in cardiovascular diseases as well as other inflammatory 
diseases. Cytokines like IL-6 and EGF family members and hematopoietic growth factor mediate 
STAT3 activation and phosphorylation. IL-6 and TGF-β costimulation activate STAT3 and this 
interaction is required for T helper 17 (TH17) differentiation and expression of IL-21 [204]. The 
cytokine IL-21 acts as autocrine factor that sustains STAT3 activation and promotes expression 
of RORγt that upregulates IL-23R expression, which in turn leads to STAT3-dependent induction 
of IL-17 [205]. STAT3 is also implicated in B cell differentiation and CD40 expression, which can 
stimulate activation of JAK3 and STAT3 [206]. Further, STAT3 phosphorylation is increased in 
atherosclerotic lesions of ApoE-/- mice fed a cholesterol-rich diet [207]. STAT3 signaling induces 
a large number of genes that are pro-inflammatory including IL-6, 10, 11, 17, 23, CXCL12, and 
cyclooxygenase-2 (COX-2) [208].      
Investigators have used several approaches to inhibit STAT3-mediated events. These include 
blocking receptors upstream of STAT3 activation, use of a variety of small molecules that directly 
block STAT3 and blocking downstream signaling events [189]. Some small molecule inhibitors 
of STAT bind to STAT monomers and/or dimers inhibiting dimerization, oligomerization or disrupt 
the SH2 domain where the tyrosine is phosphorylated by kinases. Some compounds that target 
STAT3 phosphorylation of tyrosine 705 in the SH2 domain include STA-21, Stattic, STX-0119 
and OPB-31121, all of which are currently in clinical trials and show promising results on 
experimental mice. In particular, Stattic is a small-molecule that inhibits activation, dimerization, 
nuclear translocation of STAT3 and selectively inhibits the function of STAT3 SH2 domain [209]. 
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Johnson et al. showed that Stattic prevents alterations of murine carotid arteries vasodilatation 
and superoxide production caused by Ang II-infusion [210]. This group also found that 
administration of the STAT3 inhibitor, S31-201, prevented the hypertension and endothelial 
dysfunction caused by Ang II. Further, mice with reduced STAT3 activity due to mutations in the 
S727 (SA/SA) had similar levels of systolic BP and mean arterial pressure compared to WT 
mice, but had reduced cytokines levels associated with heart failure [211]. The SA/SA mice had 
more fibrosis and they had loss of myocytes compared to WT controls. Thus, loss of STAT3 
impairs cardiac function in hypertensive hearts due to a defective myofibrillar structure. Nitric 
oxide has an important role in modulating STAT3 signaling. Kielbik et al. found that addition of 
an NO donor, DETA NONOate, to ovarian cancer cell lines inhibited STAT3 and AKT3 
phosphorylation and down regulated their cytosolic levels [212]. STATs play pivotal roles in 
various inflammatory disorders including cancer, autoimmune disease, cardiovascular disease 
and hypertension. The interplay between STATs and many other signaling pathways makes this 
a complex area to study.  
This dissertation aims to address several outstanding questions that surround vascular stimuli 
and its involvement in immune activation, specifically in monocytes, which are precursors to 
many immune cells in hypertension. During hypertension, vessels are exposed to mechanical 
forces including cyclical stretch that alter the microenvironment of the endothelium and lead to 
the development of pro-inflammatory events. In Chapter II, we test the hypothesis that 
hypertensive levels of mechanical stretch on endothelial cells promotes human monocyte 
activation and differentiation. In Chapter III, we test the hypothesis that hypertension in mice 
promote activation and differentiation of monocyte and DCs in a similar fashion to human cells. 
Finally, in Chapter IV, we attempted to engineer human induced-pluripotent stem cells to create 
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a more personalize method to study the effects of mechanical stretch on cells from the same 
patients. The findings from the various studies in this dissertation enhance our understanding of 
how hypertensive stimuli on vessels such as increased mechanical stretch can lead to the 
activation of immune cells and their differentiation to more specialized subsets, and thus can 
sustain inflammatory events that are prevalent in hypertension.     
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Introduction 
In 2016, hypertension was ranked as the leading risk factor for global burden of disease in both 
developed and underdeveloped countries [213]. Hypertension affects 30% of Western 
populations and is a major source of morbidity and mortality by promoting atherosclerosis, renal 
disease, stroke and heart failure [125]. In the past 10 years, it has become evident that activated 
immune cells infiltrate the kidney and other organs and that these cells contribute to the end-
organ damage. In particular, monocytes seem to play a particularly important role in 
hypertension. Wenzel et al. showed selective ablation of LysM+ myelomonocytic cells in mice 
completely prevented Ang II induced hypertension and prevented the endothelial dysfunction 
and vascular oxidative stress generally observed in this model [99].  
The mechanism by which monocytes promote hypertension remains undefined but likely 
involves transformation into activated states or into other cell types, including macrophages and 
monocyte-derived DCs. Indeed, De Ciuceis et al. found that mice lacking macrophage colony-
stimulating factor, required for stimulation of macrophage formation from monocytes, are 
protected against blood pressure elevation [136]. Further, these mice are protected from 
vascular remodeling, vascular superoxide production and the alteration of endothelium-
dependent vasodilation that normally accompanies hypertension [136]. Likewise, monocyte-
derived DCs seem to play a critical role in hypertension. DCs potentially activate T cells, which 
are essential for full development of hypertension [125]. We have shown that in hypertension, 
DCs accumulate isolevuglandin-adducted proteins that are immunogenic, and that adoptive 
transfer of DCs from hypertensive mice primes hypertension in recipient mice. DCs of 
hypertensive mice produce large quantities of cytokines including IL-6, IL-23 and TNFα and 
exhibit enhanced ability to drive proliferation of T cells from other hypertensive mice [139]. These 
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cytokines are activated in response to the phosphorylation of STAT3, which is known to skew T 
cells towards TH17 differentiation [214]. The production of IL-17 by such cells is critical for 
maintenance of Ang II-induced hypertension and vascular dysfunction [129]. Indeed, we have 
observed increased IL-17A producing T cells in the circulation of hypertensive humans [132].   
Circulating monocytes in humans have been classified into three subpopulations depending on 
their surface expression of the TLR4 co-receptor CD14 and the FcγIII receptor CD16 [101]. Most 
circulating monocytes are classified as “classical” and exhibit surface expression of CD14 and 
little or no CD16 (CD14++CD16-). These are thought to represent cells newly released from the 
bone marrow, and they circulate for approximately one day before either dying, transmigrating 
or transforming into another phenotype [100]. Non-classical monocytes, characterized by their 
expression of CD16 and low levels of CD14 or CD14 lowCD16++, and are known to expand in 
inflammatory states. Upon stimulation, these CD14lowCD16++ cells exhibit increased production 
of TNFα [113]. In 1988, a small population of monocytes expressing both CD14 and CD16 was 
identified [215], subsequently termed intermediate monocytes or CD14++CD16+ [121]. These 
cells are also expanded in inflammatory states such as rheumatoid arthritis, psoriasis and 
peripheral artery disease [107, 108, 216, 217]. Recent deuterium labeling studies indicate that 
intermediate and non-classical monocytes arise sequentially from the CD14 population [100]. 
When placed in culture, classical monocytes acquire increasing levels of CD16 with time [215]. 
The population of monocytes that gives rise to human monocyte-derived DCs remains poorly 
defined, but includes CD16+ cells [89]. Another population are monocytes that express the 
dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN) or CD209 DC receptor, which 
interacts with the leukocyte cell-derived chemotaxin 2 (LECT2). LECT2 is crucial for the process 
of adhesion and rolling of DCs on endothelial cells and can mediate macrophage activation and 
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protection against bacterial sepsis [218]. The expression of CD209 on DCs is considered a 
marker of maturation [219].  
A potential source of monocyte activation in hypertension is interaction of these cells with the 
vascular endothelium. In this regard, Randolph et al. showed that monocytes cultured with 
endothelial cells that had been stimulated with IL-1β, LPS or zymosan particles differentiate into 
either DCs or macrophages depending on reverse transmigration through the endothelium [167]. 
These investigators further showed that CD16+ cells are more likely to reverse transmigrate and 
that reverse transmigration of monocytes promotes the formation of a CD16+ population [220]. 
A feature of hypertension that can activate the endothelium is increased mechanical stretch. 
Indeed, increased cyclic stretch activates transcription factors including AP1, the cAMP 
responsive binding protein, NFκB in human endothelial cells [221], and a variety of signaling 
molecules including ERK1/2, the focal adhesion kinase pp125fak, PI3 kinase and p21Ras [222-
224]. Gene array studies have indicated that endothelial stretch increases expression of 
inflammatory mediators including IL-6, IL-8, MCP-1 and VCAM-1 [169]. These events promote 
monocyte adhesion, rolling and transmigration through the endothelium [92], and some are 
redox sensitive [225]. Hishikawa and Luscher showed that 10% stretch of human aortic 
endothelial cells enhances superoxide production, mediated initially by the NADPH oxidase and 
subsequently by the NO synthase depending on the presence of tetrahydrobiopterin [180].  
In the present study, we examined the role of endothelial mechanical stretch and STAT3 in 
promoting transformation of co-cultured human monocytes to the intermediate phenotype and 
to cells bearing DC properties. We also examined monocyte subsets and STAT phosphorylation 
status in humans with hypertension. Our findings provide new insight into how altered 
mechanical forces in the vessel can promote immune activation.     
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Material and Methods 
Human subjects 
We performed three studies: one involved obtaining monocytes from normotensive subjects to 
analyze their response to endothelial stretch. For this analysis, we included male and female 
normotensive participants who had blood pressures between less than 135/80 mmHg. In a 
second study, we examined the phenotype of circulating monocytes from 20 normotensive 
subjects, 52 subjects with mild hypertension (systolic BP from 130 mmHg to 140 mmHg), and 
60 subjects with more severe hypertension (systolic BP >140 mmHg). In a third study, we 
recruited 15 normotensive subjects and 12 hypertensive subjects for analysis of phospho-STAT 
levels in circulating monocytes. For this third study, participants were considered hypertensive 
if they had a systolic blood pressure higher than 140 mmHg, a diastolic blood pressure higher 
than 90 mmHg or had a diagnosis of hypertension and were currently treated with anti-
hypertensive agents. Normal and hypertensive volunteers were included between ages 18-55.   
Exclusion criteria included the following: 1) Autoimmune disease or history of inflammatory 
diseases; 2) Recent vaccinations, within the last 3 months; 3) Confirmed or suspected causes 
of secondary hypertension; 4) Severe psychiatric disorder; 5) HIV/AIDS; 6) Current treatment 
with steroids or antihistamines; 7) Liver or renal disease and 8) History of cancer. Protocol 1 and 
3 were approved by the Vanderbilt Institutional Review Board and conformed to standards of the 
US Federal Policy for the Protection of Human Subjects. The Ethics Committee of Jagiellonian 
University approved protocol two. Written informed consent was obtained from all participants. 
Demographic and clinical characteristics are shown in Table 2-1 and Table 2-2.  
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Table 2-1: Clinical characteristics of patients studied for comparison of circulating monocytes  
 
ACEi = angiotensin converting enzyme inhibitor 
ARB = angiotensin AT1-receptor blocker 
BB = beta-blocker 
1B= alpha-1 adrenergic receptor antagonist 
CCB + BB = nifedipine and metoprolol 
CCB + α1B = amlodipine and doxazosin  
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Table 2-2: Demographics of patients studied for analysis of phospho-STAT in circulating 
monocytes 
 
ACEi = angiotensin converting enzyme inhibitor 
ARB = angiotensin AT1-receptor blocker 
HCTZ = hydrochlorothiazide 
BB = beta-blocker 
1B = peripheral alpha-1 adrenergic receptor 
antagonist 
CCB + BB = nifedipine and metoprolol 
CCB + α1B = amlodipine and doxazosin  
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Human aortic endothelial cells  
Human aortic endothelial cells (Lonza, Walkersville, MD, USA) were plated on T-75 plates with 
an initial passage ranging from 3 to 7 and fed every other day with EBM-2 medium (Lonza) 
containing EGM-2 growth factors and supplements (Lonza) and 2% fetal bovine serum (FBS) or 
Vascular Cell Basal Medium (ATCC®) with Endothelial Cell Growth Kit-VEGF (ATCC® PCS-
100-041) and 5% anti-anti (100X, Gibco). Once cells reached 100% confluency, they were split 
with 0.25% Trypsin-EDTA (1X) (Gibco) and cultures were kept in 37°C incubators with 5% CO2.  
Monocyte isolation and monocyte-human aortic endothelial cells cultures 
HAECs (Lonza, Walkersville, MD, USA) were grown to confluency on flexible 6-well culture 
plates that permit uniaxial stretch (Flexcell® International Corporation, Burlington, NC, USA). 
These were coated with collagen I and 1% gelatin cross-linked with 0.05% of glutaraldehyde.  
Peripheral blood mononuclear cells (PBMCs) were isolated from blood collected in preparation 
tube with sodium heparin by Ficoll-density gradient centrifugation (400 rpm, 30 minutes, room 
temperature). CD14+ monocytes were further isolated from PBMCs using negative selection with 
the monocyte isolation kit (Miltenyi Biotec 130-096-537; Miltenyi Biotec, Auburn, CA, USA) as 
previously described [149]. Monocyte purity was confirmed by flow cytometry using an anti-CD14 
conjugated antibody and an 80 percent or higher purity was considered viable for experimental 
purposes. Monocytes from each volunteer were added to the endothelial cells previously grown 
on Uniflex® 6-well culture plates so that we could simultaneous examine the response of one 
million monocytes to endothelial cells undergoing 5% and 10% uniaxial stretch. In indicated 
experiments, 6% and 8% stretch was applied. In some experiments, one million human 
monocytes were added to Uniflex® 6-well culture plates coated with collagen I and Pronectin® 
(RGD) (Flexcell® International Corporation) in the absence of HAECs.  
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Cyclic stretch application  
The FX-5000 (Flexcell® International Corporation), a computer-driven strain unit, was used to 
induce the cyclic mechanical stretch on the monocyte-HAEC monolayers. Uniflex® culture 
plates are placed on BioFlex® gaskets and placed on greased Arctangle™ Loading Stations™ 
on the BioFlex® baseplate where cells can be exposed to either 5% (normal) or 10% 
(hypertensive) uniaxial stretch. This unit is then placed in the culture incubator and provides 
mechanical stretch that is applied to the flexible membranes on the plates by applying a 
vacuum that deforms such membranes downward. Compressed air with 30% or lower level of 
humidity was also applied to the Flexcell® Tension FlexLink® for 48 hours. The loading 
regimen was for 48 hours of uniaxial cyclical, 5% and 10% elongation stretch, 1 Hz, and ½ 
sine curve using the Flexcell® Stretch Unit.  
Transwell and conditioned media experiments 
Transwells® (Costar) permeable 24 mm insert for 6-well plates with 0.4 µM polyester membrane 
were placed on Flexcell® Transwell Holders for Uniflex® 6-well culture plates coated with 
collagen I (Flexcell® International Corporation) and 1% gelatin cross-linked with 0.05% of 
glutaraldehyde. Using this set-up, monocytes were added to the transwells limiting the direct cell 
contact with confluent HAECs. Once monocytes were added, HAECs were exposed to either 
5% or 10% cyclical stretch for 48 hours. In other experiments, HAECs cultured on Uniflex® 6-
well culture plates coated with collagen I and 1% gelatin cross-linked with 0.05% of 
glutaraldehyde were exposed to 5% or 10% cyclical stretch for 48 hours and conditioned media 
was extracted from these cultures and supplemented with 2% FBS. Conditioned media was 
stored in -80°C until use and within 6 months of storage. Monocytes isolated from PMBCs of 
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normotensive humans were cultured with the conditioned media from HAECs for 48 hours in 
static conditions.        
Flow cytometry 
Single cell suspension and surface staining: Monocyte populations were collected from the 
HAEC co-culture by including the cells in suspension and those that adhered to the endothelial 
cell layer. Adhered monocytes and endothelial cells were released in suspension by digesting 
the collagen I and 1% gelatin coating with Collagenase A (1 mg/ml, Roche), Collagenase B (1 
mg/mL, Roche) and DNase I (0.1 mg/mL, Sigma) in RPMI 1640 medium with 10% FBS for 30 
minutes at 37°C. Adhered monocytes cultured on non-coated plates were detached using 1X 
PBS with 2 mM of EDTA for 10 minutes and placed on ice. In other experiments, PBMCs were 
isolated by Ficoll-density gradient centrifugation from 20 milliliters of blood of normotensive and 
hypertensive individuals and directly stained with various markers for flow cytometry. Single cell 
suspensions were stained for flow cytometry using the following directly conjugated antibodies 
purchased from Biolegend (San Diego, CA), BD Bioscience (San Jose, CA) and 
EBioscience/Thermofisher (San Diego, CA): Pacific LIVE/DEAD™ Fixable Violet Dead Cell 
Stain (Life Technologies); PECy7-conjugated anti-CD209 (BioLegend); APC-CY7-conjugated 
anti-CD83 (BioLegend); APC-CY7-conjugated anti-CD163 (BioLegend); PerCPCY5.5-
conjugated anti-CD14 (eBioscience); AmCyan-conjugated anti-CD16 (BD Bioscience). A known 
quantity (50 µL) of calibration or counting beads (123count eBeads, eBioscience) was added to 
each sample prior to analysis. BD FACSCanto II system was used to run the samples and 
FlowJo® was used for data analysis. Gates for each antibody stain were determined by 
Fluorescent minus one (FMO) controls and confirmed using isotype controls. We employed 
live/dead stains to eliminate non-viable cells and selected only single cells for analysis (Figure 
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2-1B). For freshly isolated human monocytes, we used a gating strategy as described by 
Urbanski et al. [96]. Results were normalized using bead count and expressed as total number 
of cells. 
Intracellular staining for phosphorylated STAT3, STAT1 and Isolevuglandin-adducts: Human 
cells were washed and stained first with Pacific LIVE/DEAD™ Fixable Violet Dead Cell Stain 
(Life Technologies). Human single cell suspensions were then washed and stained with 
indicated surface antibodies (described above) for 15 minutes at 4°C. Cells were immediately 
fixed and permeabilized after staining with FIX & PERM® Cell Fixation & Permeabilization Kit 
(ThermoFisher) by adding 100 µL of Reagent A and incubating for 15 minutes in the dark at 
room temperature. Cells were washed with 3 mLs of wash medium (1XPBS + 0.1% NaN3 + 5% 
FBS). Cells were permeabilized using 100 µL of Reagent B and 3 µLs of either PE-conjugated 
anti-pSTAT3 (S727) (BD Bioscience), FITC-conjugated anti-pSTAT3 (Y705) (eBioscience), 
APC-conjugated anti-pSTAT1 (eBioscience) or APC-conjugated anti-pSTAT3 (Y705) 
(eBioscience) and incubated for 20 minutes at room temperature in dark. In other experiments, 
the D11 ScFv antibody was used to identify isolevuglandin-lysine adducts independent of protein 
backbone [139], which was labeled with a fluorochrome using the Fluor 488 Antibody Labeling 
kit (APEX™, Invitrogen). Cells were permeabilized using 100 µL of Reagent B and 5 µLs of 
Alexa-fluor 488 conjugated-D11 and incubated for 20 minutes. Cells were washed with 3 mLs of 
wash medium and resuspended in MACS buffer for flow cytometry analysis. Results were 
normalized using bead count and expressed as total number of cells or mean fluorescent 
intensity (MFI).  
FlowSight® Imaging Flow Cytometer: Human monocytes and HAECs cultures undergoing 5% 
or 10% stretch for 48 hours were released in suspension by digesting plate coating with 
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Collagenase A (1 mg/ml, Roche), Collagenase B (1 mg/mL, Roche) and DNase I (0.1 mg/mL, 
Sigma) in RPMI 1640 medium with 10% FBS for 30 minutes at 37°C. Cells were then stained 
with surface markers PerCPCY5.5-conjugated anti-CD14 and PeCy7-conjugated anti-CD83 at 
a 1:10 concentration in MACS buffer (Miltenyi). Cells were then washed and fixed using the FIX 
& PERM® Cell Fixation & Permeabilization Kit (ThermoFisher). Intracellular staining was done 
along with 100 uL Reagent B (permeabilization) and PE-conjugated anti-pSTAT3 (Y705) (1:5 
concentration) and Sytox® Green Nucleic Acid Stain (Life Technologies, 1:5000 concentration) 
for 20 minutes at room temperature. Cells were washed and imaged using FlowSight® Imaging 
Flow Cytometer at the Flow Cytometry Shared Resources core at Vanderbilt University.   
 Co-Immunoprecipitation and Western Blotting  
For the following experiments, monocytes were isolated from the monocyte-HAEC cultures using 
the negative selection for human CD31 MicroBeads Kit human (Miltenyi Biotec). Co-
immunoprecipitation (co-IP) and Western blotting were performed as previously described [149], 
cells were lysed in 150 uLs of the lysis buffer solution, 10 mLs of RIPA buffer (Sigma) and one 
tablet of complete Tablets protease inhibitor cocktail (Roche) and one tablet of the PhosSTOP 
EASYpack phosphatase inhibitor cocktail (Roche). Protein was quantified using the Pierce™ 
BCA Protein Assay Kit (ThermoScientific). For co-IP, samples (20 µg of protein) were incubated 
with total STAT3 antibody (124H6, Cell Signaling Technology) at 1:150 concentration for 1 hour 
at 4°C and 15 µLs of Protein A/G PLUS-Agarose (sc-2003) were added to lysates and gently 
rocked at 4°C overnight. Immunoprecipitated samples or protein samples (20 µg) were 
separated by SDS-PAGE and transferred to a nitrocellulose membrane and blocked with 5% 
milk and 1% BSA in 1X TBS-T as previously described [226]. Membranes were probed with 
primary antibody total STAT1 antibody (D1K9Y, Cell Signaling). Membranes were labeled using 
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horseradish peroxidase (HRP)-conjugate and detected with chemiluminescence solution using 
the SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo Scientific). Membranes 
were imaged with a BioRad ChemiDoc Imager. Blots were then stripped for 15 minutes and re-
probed using an antibody for total STAT3 (Cell Signaling). Densitometry was performed using 
the BioRad Image Lab software and bands of interest were normalized to total STAT3.  
Quantitative RT- PCR  
Monocytes were lysed in RLT buffer with 1% of β-mercaptoethanol and RNA was extracted using 
the RNeasy Mini Kit (Qiagen). RNA quantity and purity was measured using a 
spectrophotometer. RNA was used for reverse transcriptase cDNA synthesis using both iScript 
cDNA synthesis kit (BioRad, Hercules, CA, USA) or the High Capacity cDNA reverse 
transcriptase kit (Applied Biosystems). Samples were evaluated for human IL-6, IL-1β, IL-23, 
TGF-β, CD168, p22phox, CCL4, IL-18, CCL2, MMP8 and TNFα using Taqman primers. Relative 
quantification was determined using the comparative CT method where samples were 
normalized to GAPDH and calibrated to the average of the control group (5% stretch).  
Visualization of monocytes with endothelial cells in co-cultures    
One to two million human monocytes isolated from PBMCs of normotensive people were 
incubated with 12 µM of CellTracker™ Green CMFDA Dye (C2925, ThermoFisher Scientific, 
Waltham, MA, USA) in EBM2 medium (Lonza) for 30 minutes at 37°C according to 
manufacturer’s instructions. After incubation, cells were washed with medium and one million 
fluorescently tagged with monocytes were added to wells containing either confluent HAECs on 
collagen I/gelatin coated 6-well stretch plates or without the presence of endothelial cells in 6-
well stretch plates coated with collagen I or Pronectin® (RGD, Flexcell® International 
Corporation). Endothelial-containing cultures or monocytes alone were exposed to either 5% or 
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10% levels of continuous uniaxial stretch for 24 hours. Cells were subsequently washed with 1X 
PBS and the remaining cells were fixed with 4% paraformaldehyde (PFA) solution for 15 minutes 
at room temperature. The cells were then permeabilized with 0.5% Triton X-100 (Sigma) in 1X 
PBS for 30 minutes at room temperature. Cells underwent several washes in PBS and were 
blocked with goat serum solution (5% goat serum and 2.3 % glycine in PBS) for 1 hour at room 
temperature. Cultures with endothelial cells were then stained with the primary purified anti-
human CD54 (ICAM-1, HA58, Biolegend, San Diego, CA, USA) at a 1:100 concentration in goat 
serum solution for 1 hour at room temperature followed. Cells were then stained with the 
ReadyProbes secondary antibodies conjugated with Alexa Fluor™ 594 dyes goat anti-mouse 
antibody (R37121, ThermoFisher Scientific) using one drop per mL of PBS and incubation for 
30 minutes at room temperature. Finally, all plates’ flexible membranes were mounted unto glass 
slides and ProLong® Gold antifade reagent with DAPI (ThermoFisher Scientific) was used to 
stain for cells’ nucleus before adding the coverslip. Imaging of the slides was performed using 
an EVOS™ FL Imaging System (ThermoFisher Scientific). Adhered monocytes were counted 
using ImageJ software in three random fields and an average was calculated and used as a 
graphing representative.        
For imaging with confocal microscopy, membranes were fixed in 4% PFA for 15 minutes at room 
temperature, washed with PBS and then blocked for one hour in Dako Serum Free Protein Block 
(DSFPB) (Agilent Technologies, Santa Clara, CA). Membranes were incubated with purified anti-
CD83 antibody (BioLegend; category number 305301) or isotype matched control (Biolegend; 
category number 400102) in DSFPB overnight at 4oC, washed in PBS, and then probed with 
Alexa Fluor 647 labeled anti-Murine IgG raised in goat (ThermoFisher Scientific) for 30 minutes. 
Following washing in PBS, membranes were stained with anti-CD31-FITC (BioLegend; category 
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number 303103) and anti-CD14-Alexa Fluor 594 (BioLegend; category number 325630) for two 
hours at room temperature. Samples were washed in PBS and counterstained with DAPI for 10 
minutes. Membranes were washed in PBS and then mounted on glass-bottomed dishes. 
Immunofluorescent images were then acquired using a Zeiss Cell Observer SD confocal 
fluorescent microscope (Zeiss, Oberkochen, Germany). 
Compounds 
Several compounds were used to determine the mechanisms of processes including STAT3 
inhibitor, Stattic (5 µM, Sigma), tofacitinib citrate (100 ng/µL, Sigma), tocilizumab (100 ng/mL, 
Genentech), neutralizing antibody anti-IL-6 (10 µg/mL, BioLegend) and an IL-6/IL-6R fusion 
protein (hyper IL-6, 100 ng/mL) provided by Dr. Stefan Rose-John. In addition, we used DETA 
NONOate (300 µM/1000 µM, Cayma), Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) 
(ab120136, 100/ 300/1000 µM, ABCAM) and IsoLG-adducts scavenger, 2-hydroxybenxylamine 
(2-HOBA) (10 μM, Vanderbilt). Additional pharmacological inhibitors were used including tempol 
(100 µM, Sigma), ebselen (1 µM, Sigma), mito-ebselen (1 nM, Dikalov laboratory), catalase (20 
µg/µL, Sigma), PEG-catalase (500 U/mL, Sigma), valdecoxib (100 nM, Cayman) and 
napabucasin (1 µM/L, MedChem). All these concentrations were determined by dose-curve 
experiments or previously published literature tested at in vitro cell culture conditions.  
Enzyme-Linked Immunosorbent Assay (ELISA) 
Human aortic endothelial cells were exposed to 5% or 10% cyclic mechanical stretch for 48 
hours. Conditioned media from these cell cultures was collected and spun down to eliminate 
cellular debris. IL-6, LECT 2, and High Mobility Group Box-1 (HMGB-1) proteins were quantified 
using ELISA kits from LS-Bio, Affymetrix and IBL International, respectively. ELISAs were 
performed according to manufacturers’ instructions. A standard curve was created using the 
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standards provided and serial dilutions were performed (1:2, 1:10, 1:20, 1:50, 1:100) and added 
to each well. Samples were also added to the appropriate wells and incubated for the indicated 
time points. ELISA plates were washed in wash buffer and detection antibody was added. Avidin-
HRP was added to each for detection and a substrate for HRP was added for color change and 
to be read at a 450 nm wavelength.       
Statistics   
All data are expressed as mean ± SEM. One tailed- paired and unpaired Student’s t-tests were 
used to compare two groups. In case of the non-normality, the nonparametric test one-tailed 
Mann-Whitney U test was used. When examining the effect of varying endothelial percent stretch 
on monocyte transformation to the intermediate phenotype, we employed one-way ANOVA with 
Student Newman Keuls post-hoc test. When examining the effect of DETA-NONOate, we 
employed the Friedman’s multiple comparison test followed by the Dunn’s post-hoc test. To 
compare the distribution of monocyte subtypes in normotensive humans vs humans with mild or 
severe hypertension, we employed one-way ANOVA. To compare pSTAT levels in monocytes 
from normotensive and hypertensive subjects, we employed two-way ANOVA with Student 
Newman Keuls post-hoc test. P values are reported in the figures and were considered 
significant when less than 0.05. Power analyses for the various experiments are provided in 
Table 2-3.  
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Table 2-3. Power achieved for each experimental condition  
 
* For intermediate monocytes; ᵵ for pSTAT3 (Y) MFI from normotensive human intermediate vs 
classical monocytes. 
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Results  
Hypertensive mechanical stretch in human endothelial cells promotes monocyte 
activation and differentiation: It has been previously reported that endothelial cells activated 
by zymosan, LPS or IL-1 promote conversion of monocytes to DCs [167]. A feature of 
hypertension that activates endothelial cells is increased mechanical stretch. We therefore 
isolated CD14+ monocytes from PBMCs of normotensive humans and co-cultured these with 
HAECs undergoing 5% or 10% mechanical stretch for 48 hours as shown by the illustration in 
Figure 2-1A. The intermediate monocyte CD14++CD16+ population (Figure 2-1B, 1C) and the 
CD14++CD209+ population (Figure 2-1B, 1D) were significantly increased in the co-cultures with 
HAECs undergoing 10% vs. 5% stretch. The non-classical monocyte population defined as 
CD14lowCD16++ displayed a trend to increase in response to 10% endothelial stretch (Figure 2-
1E). The macrophage population defined as CD14+CD163+ (Figure 2-1F) and the classical 
monocyte population defined as CD14++CD16- (Figure 2-1G) were not different between 
experimental groups. Another marker of monocyte activation and DC development is CD83 
[227], however only a few monocytes expressed CD83+ after co-culture (Figure 2-1H) and these 
were not changed by endothelial stretch. In keeping with the state of monocyte activation, 10% 
endothelial stretch promoted a striking upregulation of monocyte mRNA for the cytokines IL-6, 
IL-1β, IL-23, TNFα, and CCL4 compared to 5% stretch (Figure 2-1I). In contrast, stretch did not 
affect monocyte expression of TGF−1, MMP8, CCL2, IL-18, or CD168 (Figure 2-2). 
Intermediate levels of endothelial stretch ranging from 6% to 8% failed to alter the phenotype of 
human monocytes (Figure 2-3A). There was also no difference in the percent of live cells 
between 5% and 10% endothelial stretch (Figure 2-3B).  
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Figure 2-1: Hypertensive mechanical stretch in human endothelial cells promotes monocyte 
activation and differentiation. Human CD14+ monocytes were isolated by magnetic sorting from 
PBMCs of normal human volunteers and cultured with HAECs exposed to cyclical stretch. A. Schematic 
of methods and (B) gating strategy for phenotyping human monocyte subsets including classical 
(CD14
++
CD16-), intermediate (CD14
++
CD16
+
), non-classical monocytes (CD14lowCD16++) and the 
CD14
++
CD209
+
cells comparing 5% and 10% stretch are shown. C. Changes in numbers of cells for each 
subject are depicted by connected lines for CD14
++
CD16
+ 
(n = 9) and (D) CD14++CD209+, (E) 
CD14lowCD16++ (F) macrophage population (CD14
+
CD163
+
), (G) CD14
++
CD16
-
, (H) CD14
-
CD83
+ 
(n=10). 
I. Relative monocyte mRNA expression of IL-6, IL-1β, IL-23, TNFα and CCL4 in adhered and monocytes 
in suspension (5%, n=15; 10%, n=16). Comparisons were made using one-tail paired t-tests (*p<0.05, 
**p<0.01). 
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Figure 2-2: Hypertensive mechanical stretch in human endothelial cells effects on monocyte gene 
profile. Human CD14+ monocytes were isolated from PBMCs of normal human volunteers and cultured 
with HAECs exposed to 5% or 10% stretch for 48 hours. Relative monocyte mRNA expression of TGFβ-
1 (n=8), MMP8 (5%, n=3; 10%, n=4), CCL2 (n=5), IL-18 (n=5) and CD168 (n = 8) in monocytes. Statistical 
differences were determined using one-tailed unpaired t-tests (**p<0.01).  
 
 
Figure 2-3: Intermediate levels of endothelial stretch and effects on monocyte phenotype. A. 
Human CD14+ monocytes were isolated from PBMCs of normal participants and cultured with HAECs 
undergoing 5% (n = 10), 6% (n = 4), 8% (n = 3) and 10% (n = 10) cyclical stretch for 48 hours. Mean data 
showing the percent number of intermediate monocytes in response to each stretch percentile. B. Mean 
data showing the percent number of live cells after 48 hours of endothelial 5% and 10% stretch. 
Comparisons were made using one-way ANOVA with Student Newman Keuls post-hoc test and one-
tailed paired t-tests (***p<0.001, ****p<0.0001).  
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Hypertensive mechanical stretch on endothelial cells promotes STAT3 activation in co-
cultured monocytes: Increased expression of IL-6, IL-1β and IL-23 resemble a cytokine 
response typical of STAT3 signaling [228]. In addition, STAT3 activation has been identified as 
a checkpoint for FLT-3-regulated DC development [229]. We therefore sought to determine 
whether STAT3 plays a role in monocyte activation and differentiation when exposed to HAECs 
undergoing stretch. STAT3 activation occurs upon phosphorylation of tyrosine (Y) 705 and/or 
serine (S) 727. When activated, STAT3 can also form a heterodimer with STAT1. Using 
intracellular staining, we found that the CD14++CD16+ intermediate (Figure 2-4A, 4C-E) and the 
CD14++CD209+ populations (Figure 2-4B, 4F-H) had a significant increase in pSTAT3 (Y705), 
pSTAT3 (S272) and pSTAT1 when cultured with endothelial cells undergoing 10% stretch. We 
also observed an increase in STAT3 and STAT1 phosphorylation in cells that remained 
CD14++CD16-, but not in the non-classical monocytes (Figure 2-5A-B). Given that both STAT3 
and STAT1 are activated in monocytes that underwent transformation, we considered the 
possibility that this involved heterodimerization of the two STAT isoforms, however, we were 
unable to detect association of the two using co-immunoprecipitation (Figure 2-5C). Moreover, 
we were unable to detect fluorescence resonance energy transfer between STAT1 and STAT3 
using flow cytometry-based method (data not shown).   
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Figure 2-4: Effect of endothelial stretch on STAT3 activation in co-cultured monocytes. Human 
CD14+ monocytes were isolated from buffy coats of normal human volunteers and cultured with HAECs 
exposed to 5% or 10% cyclical stretch. A. Representative flow cytometry plots are shown for intracellular 
staining of STAT3 phosphorylation in the tyrosine (Y) 705 and the serine (S) 727 and STAT1 
phosphorylation in the Y701 in the CD14++CD16+ intermediate monocytes and (B) the CD14++CD209+ 
cells in the 5% stretch (blue), 10% stretch (red), and the dashed line represents FMO control. C-E. 
Changes in numbers of intermediate monocytes between 5 and 10% endothelial cell stretch expressing 
pSTAT3 (Y), pSTAT3 (S), and pSTAT1 are depicted by connected lines. F-H. Changes in numbers of 
CD14++CD209+ cells expressing pSTAT3 (Y), pSTAT3 (S), and pSTAT1 between 5% and 10% 
endothelial cell stretch. Comparisons were made using one-tail paired t-tests (n = 9, * p<0.05, ** p<0.01).      
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Figure 2-5: STAT3 and STAT1 expression in other monocyte subpopulations when culture with 
endothelial cells undergoing mechanical stretch. Human CD14+ monocytes were isolated from 
PBMCs of normal human volunteers and cultured with HAECs exposed to 5% or 10% stretch for 48 
hours. A. Individual values for number of cells within the classical monocyte population expressing p-
STAT3 (Y), p-STAT3 (S), and p-STAT1 for each subject are indicated by connected lines (n= 9). B. 
Values for total number of cells within the CD14lowCD16++ non-classical population expressing p-STAT3 
(Y), p-STAT3 (S), and p-STAT1 for each participant (n = 8). C. Proteins from monocyte cell lysates (20 
µg) in cultures with HAECs exposed to 5% or 10% stretch after 48 hours were immunoprecipitated with 
total STAT3 and subjected to Western Blot detection of total STAT1 protein. Representative of two 
independent experiments are shown (n=8). Statistical differences were determined using one-tailed 
paired t-tests (*p<0.05).      
 
STAT3 plays a role in monocyte differentiation and activation during hypertensive 
mechanical stretch of endothelial cells: To determine a specific role of STAT3 in 
differentiation of monocytes during stretch, we employed Stattic, a nonpeptidic small molecule 
that selectively inhibits the function of the STAT3 SH2 domain [209]. Addition of Stattic to the 
cell culture reduced formation of the CD14++CD16+ intermediate monocyte population (Figure 2-
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6A, 6C) and CD14++CD209+ DC population in response to 10% stretch (Figure 2-6B, 6D). 
Likewise, Stattic reduced pSTAT3 (Y), pSTAT3 (S), and pSTAT1 in the CD14++CD16+ 
intermediate (Figure 2-6E-G) and the CD14++CD209+ monocyte populations (Figure 2-6H-J). 
Further, we found that addition of Stattic to monocyte-HAEC cultures undergoing 10% stretch 
reduced upregulation of mRNA for the cytokines IL-6, IL-1β, and IL-23 (Figure 2-6K).  
Next, we sought to determine mechanisms by which endothelial cells undergoing stretch could 
activate monocytes and promote STAT3 phosphorylation in adjacent monocytes. Our group has 
reported an increase formation of IsoLG-adducts in monocytes and DCs of hypertensive mice 
and humans [139]. IsoLGs adduct to protein lysines and can potentially act as a neoantigen, 
which induce T cell activation and formation of cytokines. To examine IsoLG-adduct formation 
in monocyte populations in response to endothelial mechanical stretch, we used flow cytometry 
and intracellular staining using an Alexa Fluor 488-tagged single-chain antibody specific for 
IsoLG-adduct, D11 [230]. We found that the CD14++CD209+ population had the highest 
accumulation of IsoLG-adducts compared to the classical monocytes, macrophages and CD83+ 
DCs when cultures with endothelial cells undergoing 10% stretch (Figure 2-7).  
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Figure 2-6: STAT3 contributes to monocyte differentiation and activation during hypertensive 
mechanical stretch of endothelial cells. Human CD14+ monocytes were isolated from PBMCs of 
normal human volunteers and cultured with HAECs exposed to 10% or 10% stretch plus STAT3 inhibitor 
(5 µM), Stattic, for 48 hours. A. Flow cytometry gating examples are shown for the CD14++CD16+ 
intermediate monocyte population and (B) the CD14++CD209+ cells. C. Individual data point for the effect 
of Stattic on the number intermediate monocytes and (D) CD14++CD209+ cells for each subject. E-G. 
Effect of Stattic on total number of cells expressing pSTAT3 (Y), pSTAT3 (S), and pSTAT1 within the 
intermediate monocyte population and (H-J) the CD14++CD209+ population. A total of n=7 participants 
per group were used. K. Relative monocyte mRNA expression of IL-6, IL-1β, IL-23 (10%, n= 11; 10% + 
Stattic, n = 9), TNFα (n = 7), and CCL4 (n =4) in monocytes. Comparisons were made using one-tail 
paired t-tests (*p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).      
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Figure 2-7: Accumulation of IsoLG-adducts in different monocyte-derived populations exposed 
to endothelial cells undergoing stretch. Monocytes isolated from PBMCs of normal subjects was 
added to endothelial cells, which underwent 5% and 10% stretch for 48 hours. IsoLG-adducts were 
measured by intracellular staining flow cytometry using Alexa Fluor 488-tagged D11 antibody. Mean 
fluorescent intensity (MFI) for IsoLG-adducts are shown for the classical, CD209 population, macrophage 
population and the DCs comparing 5% vs 10%. Two-way ANOVA with Student Newman Keuls post-hoc 
test was used (n = 8; *** p<0.001).      
 
Figure 2-8: Interleukin 6 is released by endothelial cells undergoing hypertensive mechanical 
stretch. Human aortic endothelial cells were grown to confluency and exposed to either 5% or 10% 
stretch for 48 hours. Conditioned media from HAECs exposed to various levels of stretch was used to 
detect IL-6 by ELISA and normalized according to a concentration curve. Mean values for IL-6 are shown 
as pictogram per milliliter. Statistical difference was determined using a one-tailed unaired t-test (n= 9; 
*p<0.05).      
 
Others have reported that stretch stimulates expression of IL-6 by endothelial cells, and we 
confirmed a 2-fold increase in IL-6 protein production by HAECs undergoing 10% cyclical stretch 
(Figure 2-8). IL-6 has been shown to both stimulate STAT3 activation and to be produced in 
response to STAT3 in a feed-forward fashion [231]. Addition of an IL-6 neutralizing antibody to 
the endothelial/monocyte co-cultures markedly reduced formation of intermediate monocytes 
(Figure 2-9A-B), while having no effect on the CD14++CD209+ population (Figure 2-9C). 
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STAT3 can also be activated by ROS, including hydrogen peroxide [228]. ROS, in turn can 
stimulate IL-6 production by the endothelium [232]. Increased endothelial stretch can stimulate 
ROS formation and, thus, we performed additional experiments using Tempol, a superoxide 
dismutase mimetic, or PEG-Catalase, to scavenge hydrogen peroxide. While Tempol had no 
effect (data not shown), we found that PEG-Catalase markedly reduced formation of 
intermediate monocytes in response to 10% endothelial stretch (Figure 2-9D). Similar to anti-IL-
6, PEG-Catalase did not inhibit formation of the CD209 population (Figure 2-9E). In keeping with 
these results with anti-IL-6 and PEG-Catalase, we found that these interventions also inhibited 
pSTAT3 (S727) and pSTAT1 (Y701) and exhibited a trend to inhibit pSTAT3 (Y705) (Figure 2-
9F-G) within the intermediate monocytes. 
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Figure 2-9: IL-6 and hydrogen peroxide play a role in monocyte transformation and activation. 
Human CD14+ monocytes were isolated from PBMCs of normal human volunteers and cultured with 
HAECs exposed to 10% stretch, 10% plus anti-IL-6 neutralization antibody (10 µg/mL) or 10% plus PEG-
Catalase (500 U/mL) for 48 hours. A. Schematic of methods and flow cytometry gating representatives 
are shown for the CD14++CD16+ intermediate monocyte population exposed to 10%, 10% + anti-IL-6, 
and 10% + PEG-Catalase. B. Effect of anti-IL-6 on the total number of intermediate monocytes and (C) 
the CD14++CD209+ cells for each subject. D. Effect of PEG-Catalase on total number of intermediate 
monocytes and (E) the CD14++CD209+ cells for each participant. F. Effects of anti-IL-6 and G. PEG-
Catalase on number of cells expressing pSTAT3 (Y), pSTAT3 (S), and pSTAT1 within the intermediate 
monocyte population for each subject. Data with and without these interventions for each subject are 
shown by the connected lines. A total of n=6 participants per group and per experimental treatment were 
used. Comparisons were made using one-tail paired t-tests (*p<0.05, ** p<0.01, *** p<0.001).      
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Increased endothelial stretch has also been shown to uncouple the endothelial NO synthase 
and to reduce stimulatory phosphorylation of eNOS in endothelial cells [180, 233]. Likewise NO 
has been shown to suppress IL-6-induced STAT3 activation in ovarian cancer cells [234]. We 
therefore hypothesized that a loss of bioavailable NO might promote STAT3 activity. In keeping 
with this hypothesis, we found the NO donor DETA-NONOate (DETA NONO) dramatically 
reduced formation of intermediate monocytes (Figure 2-10A, 10C) and the activation of STAT3 
(Y), STAT3 (S), and STAT1 when added to monocytes cultures in the absence of endothelial 
cells (Figure 2-10D-F). Further, addition of this NO donor also reduced formation of 
CD14++CD209+ cells (Figure 2-10B, 10G) and activation of STAT3 (Y05), STAT3 (S727), and 
STAT1 (Figure 2-10H-J). We further found that addition of the NO synthase inhibitor L-NAME to 
monocytes undergoing 5% stretch significantly increased pSTAT3 (Y705), pSTAT3 (S272), and 
pSTAT1 levels in intermediate monocytes (Figure 2-10K).  
We considered the possibility that LECT2, a ligand for CD209, might be released by endothelial 
cells, however, we were unable to detect LECT2 released from HAECs undergoing either 5% or 
10% stretch using ELISA (data not shown). We were also unable to detect release of the HMGB-
1 chromatin binding protein, which has been shown to activate STAT3 [235], from stretched 
endothelial cells (data not shown).  
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Figure 2-10: Exposure of monocytes to NO donor inhibits human monocyte conversion and 
activation to its derived populations. Human CD14+ monocytes were isolated from buffy coats of 
normal human volunteers and cultured alone in untreated (UT) conditions, DETA-NONOate (DETA-
NONO), an NO donor, at 300µM or DETA-NONO at 1000µM concentrations in static conditions for 48 
hours. A. Flow cytometry representatives are shown for the CD14++CD16+ intermediate monocyte and 
(B) the CD14++CD209+ population. C. Values for each subject without and with DETA-NONO are shown 
for the total number of cells from the CD14++CD16+ intermediate monocytes and for the total number of 
cells expressing (D) pSTAT3 (Y), (E) pSTAT3 (S), and (F) pSTAT1 within this population. G. Effect of 
DETA-NONO on the number of CD14++CD209+ cells and the expression of (H) pSTAT3 (Y), (I) pSTAT3 
(S), and (J) pSTAT1 for each subject. A total of n= 9 participants per group were used for these 
experiments. K. Human CD14+ monocytes were cultured with HAECs exposed to 5% stretch or 5% plus 
NO synthase inhibitor, L-NAME, (1000 µM) for 48 hours. The number of CD14++CD16+ intermediate 
monocyte population expressing pSTAT3 (Y), pSTAT3 (S), and pSTAT1 for each subject are connected 
by lines. A total of n=7 participants per group were used. For panel C-J the nonparametric Friedman’s 
test followed by Dunn’s multiple comparison tests was employed. For panel K a one-tailed paired t-tests 
was used (*p<0.05, ** p<0.01, *** p<0.001). 
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We considered the possibility that the factor promoting this process of monocyte transformation 
and activation could be released from endothelial cells undergoing increased stretch and not 
necessarily require direct cell contact. We obtained evidence suggesting that the factors 
potentially mediating monocyte transformation are likely short-lived and do in fact require direct 
cell contact. Thus, we collected conditioned media from HAECs stretched alone to 5% or 10% 
for 48 hours and added this to monocytes for another 48 hours in static conditions. We found no 
differences in monocyte transformation when these were cultured with 5% or 10% stretch 
conditioned media. However, monocytes underwent transformation into the intermediate 
phenotype and the CD209 population at the same rate than the co-culture system undergoing 
stretch (Figure 2-11A-D). In addition, we tested the hypothesis that monocytes require direct cell 
contact with the endothelium to undergo transformation by using a transwell system, which 
eliminated the cell contact but allowed the transfusion of smaller compounds. Similar to the 
conditioned media experiment, we observed the same rate of monocyte transformation in the 
transwell system when endothelial cells were undergoing 5% and 10% stretch (Figure 2-11E-H) 
compared to the co-culture system. These experiments suggest that physiological levels of 
stretch on vessels might release a short-lived factor that prevents monocyte activation and 
transformation.  
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Figure 2-11: Exposure of monocyte to stretched endothelial cells in a transwell set-up or to 
conditioned media. A. Human CD14+ monocytes were isolated from PBMCs of normal human subjects 
and cultured in conditioned media supplemented with 2% FBS from HAECs that underwent stretching of 
5% and 10% for 48 hours. These cells were kept under static conditions for another 48 hours. Flow 
cytometry representatives are shown for the CD14++CD16+ intermediate monocyte and (B) the 
CD14++CD209+ population. C. Values for each subject exposed in 5% or 10% conditioned media are 
shown for the total number of cells from the CD14++CD16+ intermediate monocytes and (D) 
CD14++CD209+ population (n = 6). E. Isolated monocytes were added to transwells that were on top of 
confluent endothelial cells and these were stretched to 5% and 10% for 48 hours. Flow cytometry 
representatives are shown for the CD14++CD16+ intermediate monocyte and (F) the CD14++CD209+ 
population. G. Values for each subjects’ monocytes placed on transwells and exposed to HAECs 
undergoing 5% or 10% stretch are shown for the total number of cells from the CD14++CD16+ intermediate 
monocytes and (H) CD14++CD209+ population (n = 8, n = 12, respectively). One-tailed paired t-tests was 
used. 
 
Further, we examined the hypothesis that monocytes might adhere to the endothelium and 
themselves undergo cyclical stretch. In keeping with this, we found that 10% stretch increased 
ICAM-1 expression on endothelial cells and increased adhesion of monocytes to the HAECs 
compared to the 5% stretch controls (Figure 2-12A) after 24 hours. We also employed confocal 
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microscopy with Z stacking to interrogate the endothelial layer and the subendothelial collagen 
to visualize CD31+, CD14+ and CD83+ cells. Using this approach, we observed CD14+ 
monocytes on the surface of endothelial cells in the co-culture (Figure 2-12B). Moreover, CD83+ 
cells were observed on the surface of the CD31+ endothelial cells exposed to 10% stretch, while 
none was detected in cultures exposed to 5% stretch. We observed no monocyte or CD83 
expressing cells in the collagen/gelatin sub-endothelial space in either the 5% or 10% stretch 
experiments.  
 
To determine if stretch could directly activate monocytes we cultured monocytes in 
arginylglycylaspartic acid (RGD) -covered Pronectin® or collagen I coated stretch plates in the 
absence of HAECs, and exposed these to either 5% or 10% levels of stretch. Both Pronectin® 
and collagen I-coated stretch plates promoted monocyte adhesion (Figure 2-12C) after 24 hours, 
but neither supported monocyte transformation when exposed to stretch (Figure 2-12D) after 48 
hours. To confirm the nuclear translocation of p-STAT3 in monocytes in response to endothelial 
mechanical stretch, we performed FlowSight® techniques. We have previously shown that all 
monocyte populations have at least some degree of cells that are positive for p-STAT3, but the 
intermediate monocytes and the CD209 population express the highest amount of p-STAT3 in 
response to hypertensive stretch. We found that p-STAT3 in classical monocytes, CD14+CD83+ 
cells, and CD83+ DCs co-localizes with the nuclear stain Sytox (Figure 2-13). Thus, endothelial 
mechanical stretch promote monocyte phosphorylation of STAT3 and translocation to the 
nucleus where it can act as a transcription factor for various pro-inflammatory genes of which 
are the ones we found to be increased. has pathophysiological implications.  
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Figure 2-12:  Human monocytes require endothelial cell contact for their differentiation and 
activation during hypertensive mechanical stretch. A. Human monocytes from normal volunteers 
were isolated from buffy coats and labeled with 12µM of CellTracker™ Green CMFDA dye for 30 mins 
at 37°C in medium and added to HAEC cultures exposed to either 5% or 10% stretch for 24 hours. Plates 
were washed with 1X PBS and fixed with 4% PFA. Adhered monocytes were counted. 
Immunofluorescent microscopic images show monocytes adhered to the endothelial cells (green) and 
expression of ICAM-1 on the endothelial cell monolayer (red). Mean data showing the number of adhered 
monocytes per three random fields are illustrated (n=6). B. Human monocytes from normal volunteers 
were isolated from buffy coats and added to HAEC cultures exposed to either 5% or 10% stretch for 24 
hours. Plates were washed with 1X PBS and fixed with 4% PFA. Confocal microscopy with Z stacking 
was used to visualize CD31+ (green), CD14+ (red) and CD83+ (white) in different surfaces including the 
subendothelial space. Cells were counterstained with DAPI (n=4). C. Human CD14+ monocytes labeled 
with 12 µM of CellTracker™ Green CMFDA dye were placed on either collagen I or Pronectin® (RGD) 
coated plates without the presence of endothelial cells and were exposed to 5% or 10% cyclical stretch 
for 24 hours. Immunofluorescent microscopic images show monocytes that adhered to the collagen I and 
Pronectin® coated membranes after exposure to hypertensive mechanical stretch (n= 4). D. Human 
CD14+ monocytes were cultured alone on collagen I (n=11) or Pronectin® (n=6) coated plates and 
stretched to either 5% or 10% for 48 hours. Individual values are shown for each participant of the number 
of cells expressing CD14++CD16+ and CD14++CD209+ cells in each experimental condition. Statistical 
differences were determined using one-tailed unpaired or paired t-tests (*p<0.05).      
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Figure 2-13: Phosphorylated STAT3 localizes to the nucleus of activated monocytes and dendritic 
cells. Normal human monocytes were cultured with HAECs undergoing stretch for 48 hours. Two days 
later, cells were harvested and stained for the surface markers CD14 and CD8 and for the intracellular 
markers pSTAT3 (Y705) and Sytox, which is a nuclear stain. FlowSight® technique was used to visualize 
the cells real-time and determine the localization of phosphorylated STAT3 within the CD14+CD83-, 
CD14+CD83+ and CD14-CD83+ populations. 
 
Hypertension affects the distribution of circulating mononuclear cells in humans: In 
additional experiments, we sought to determine if hypertension is associated with an alteration 
of the phenotype of circulating monocytes. The demographics of the 132 subjects enrolled for 
this analysis are shown in Table 2-1. Using a gating strategy as published previously [236], we 
found that there is a progressive decline in the classical monocytes and a concomitant increase 
in the percent of intermediate and non-classical monocytes with increasing levels of 
hypertension (Figure 2-14A-C). In additional studies, we sought to determine if intermediate 
monocytes or non-classical monocytes exhibit evidence of STAT activation. We recruited an 
additional 15 normotensive and 12 hypertensive subjects for this analysis. The demographics of 
these subjects are shown in Table 2-2 and a representative dot plot for the different monocyte 
populations is shown in Figure 2-14D. Example histograms for STAT phosphorylation in 
normotensive and hypertensive individuals are shown in Figure 2-14E. Intermediate monocytes 
exhibited increased phosphorylation of STAT3 Y705, STAT3 S727 and STAT1 Y701 compared 
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to other monocyte populations (Figure 2-14F-H). No differences between normotensive and 
hypertensive groups were observed.  
 
Figure 2-14: Hypertension affects the distribution of circulating monocytes in humans. A. A cohort 
of normotensive (n = 20), mildly hypertensive (systolic BP ~130-140 mmHg, n = 52), and severely 
hypertensive (systolic BP >140 mmHg, n = 60) subjects were recruited and flow cytometry was used to 
analyze various monocyte populations. A. Mean values are shown for the percent of 
positive CD14++CD16- classical, (B) CD14++CD16+ intermediate and (C) CD14lowCD16++ non-classical 
monocytes comparing normotensive, mild and severely hypertensive subjects. Data were analyzed using 
one-way ANOVA. D. Representative flow cytometry dot plots showing classical, intermediate, and non-
classical subset distribution are shown. E. Histograms showing the CD14++CD16- classical, 
CD14++CD16+ intermediate, non-classical monocyte population comparing normotensive (black) and 
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hypertensive (red) subjects. The dashed line represents the Mean fluorescent intensity (MFI) for the FMO 
control. E. MFI for pSTAT3 (Y), pSTAT3 (S) (F), and pSTAT1 (G) in various monocyte subgroups in both 
normotensive (n=15) and hypertensive (n = 12) subjects. Two-way ANOVA with Student Newman Keuls 
post-hoc test was used (*p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).      
Discussion  
 
In this study, we demonstrate that exposure of human monocytes to endothelial cells undergoing 
10% mechanical stretch increases differentiation into CD14++CD16+ intermediate monocytes 
and CD14++CD209+ cells. We further show that monocytes cultured with endothelial cells 
exposed to hypertensive mechanical stretch markedly increase expression of IL-6, IL-1β, IL-23, 
CCL4, and TNFα. In addition, we found that endothelial cells undergoing hypertensive 
mechanical stretch stimulate an increase in pSTAT3 (Y), pSTAT3 (S), and pSTAT1 within these 
monocyte populations. Inhibition of STAT3 by Stattic prevented conversion of monocytes into 
the intermediate and the DC phenotype and normalized the cytokine production of these 
monocytes cultured with endothelial cells undergoing 10% stretch. Our data implicate a role of 
hydrogen peroxide and IL-6 as mediators of monocyte differentiation. We also show that 
hypertension is associated with an increase in the percentage of circulating intermediate and 
non-classical monocytes and that circulating intermediate monocytes exhibit higher levels of 
pSTAT3 (Y), pSTAT3 (S), and pSTAT1. Thus, altered mechanical forces affecting the 
endothelium can modify monocyte differentiation and activation and likely contribute to immune 
activation in hypertension.  
 
Intermediate monocytes are the least characterized of the monocyte subtypes in humans, 
however, these cells have been implicated in inflammatory diseases such as Kawasaki disease 
[106], rheumatoid arthritis [108], sepsis [109], HIV [110], acute heart failure and coronary artery 
disease [111]. Using deuterium labeling in humans, Patel and colleagues recently showed a 
sequential transition of classical monocytes that emerge from the bone marrow to the 
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intermediate and subsequently the non-classical phenotype [100]. Compared to classical 
monocytes, intermediate monocytes exhibit enhanced phagocytosis, produce higher levels of 
ROS and inflammatory mediators such as TNFα and IL1-β [97, 113, 114]. They also have the 
highest expression of the major histocompatibility complex class II antigens, including HLA-DR, 
-DP and -DQ indicating that they also possess antigen presentation functions [112]. Thus, the 
presence of high numbers of intermediate monocytes in humans with hypertension likely has 
pathophysiological implications. 
Our data are compatible with findings by Randolph et al. showing that activated endothelial cells 
can modify monocyte phenotype. They demonstrated that monocytes that transmigrate the 
endothelium convert to macrophages that remain in the subendothelial space or DCs expressing 
CD83 that reverse transmigrate the endothelium [167]. In a subsequent study, this group also 
showed that a subpopulation of CD16+ monocytes have a propensity to reverse transmigrate the 
endothelium and, upon doing so, increase their expression of CD86+ and HLA-DR. In keeping 
with this, the authors showed these monocytes potently induced allogenic T cell proliferation 
[220]. The investigators assumed cells had transmigrated the endothelial monolayer if they were 
not removed by washing the monolayer 2 hours after addition of the cells. In our study, we found 
that 10% stretch markedly enhanced monocyte binding to the endothelial surface. Our analysis 
included adhered cells and those potentially within the subendothelial space and it also 
demonstrated the presence of macrophage-like cells expressing the CD163 marker; however, 
these were not altered by the degree of endothelial stretch.  
In these experiments, we not only examined intermediate and non-classical monocytes, but also 
CD14+ cells bearing the markers CD209 and CD83. These have been employed as dendritic 
cell markers, but can be expressed on a variety of activated myeloid cells. CD209 is a C-type 
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Lectin receptor that promotes the production of IL-1 and IL-23 that can ultimately skew T cells 
to a TH17 phenotype. Levels of CD209 on whole leukocytes correlate with disease severity in 
Behçet’s Disease [237]. LECT2 acts on CD209 to induce JNK signaling in monocytes and 
endothelial cells [218]. CD209 forms a complex with TLR4 and promotes NFB activation in 
response to oxidized low-density lipoprotein (LDL) confirming the role of CD209 in innate 
immunity and antigen presentation [238]. While we were not able to detect LECT2 levels in our 
co-culture system, the increase in CD209 on monocytes could arm these cells to respond to 
signals like LECT2 or oxidized LDL in vivo. CD83 is a type-I lectin transmembrane protein 
expressed on monocyte-derived DCs and small subsets of other immune cells [239]. The 
presence of CD83 on DCs enhances their ability to evoke T cell calcium transients and 
proliferation [227]. Thus, surface expression of CD209 and CD83 may have functional 
consequences in enhancing immunogenicity of monocyte-derived cells in hypertension.  
 
There are a number of factors in the hypertensive milieu that could activate both endothelial cells 
and monocytes, including cytokines and oxidative stress [240, 241]. In this investigation, we 
focused on the role of increased endothelial stretch, which is known to stimulate endothelial cell 
cytokine production, ROS formation and expression of adhesion molecules [180]. The vessels 
affected by stretch in hypertension likely vary depending on the duration of the disease. Early in 
hypertension, there is increased stretch of large vessels; however, as hypertension is sustained, 
large vessel become stiff leading to propagation of the forward PWV into smaller resistance 
vessels [242]. Our present data therefore might explain how increased cyclic stretch in small 
vessels could promote immune activation. Consistent with this, we have previously shown that 
aortic stiffening precedes renal accumulation of T cells, monocyte and macrophages ultimately 
leading to renal dysfunction [7].  
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In these experiments, we found evidence for STAT activation in intermediate monocytes of 
humans and in monocytes exposed to endothelial cells undergoing 10% cyclical stretch as 
evidenced by phosphorylation of STAT1 at Y701 and STAT3 at S727 and Y705. Of interest, 
STAT3 is required for FLT-3-dependent formation of DCs from bone marrow derived cells [229], 
and plays an important role in production of IL-1, IL-6 and TNFα in macrophages of humans 
with coronary artery disease [228]. We also found that exposure of monocytes to endothelial 
cells undergoing 10% stretch markedly enhanced mRNA expression of these cytokines and 
STAT3 activation in these. Inhibition of STAT3 with Stattic not only inhibited cytokine production 
by human monocytes, but also reduced their conversion to intermediate monocytes and 
CD14++CD209+ cells. Thus, STAT-signaling seems to play an important role in monocyte 
differentiation and activation in hypertension.  
We made substantial efforts to identify factors released by the endothelium that would mediate 
STAT3 activation. STAT3 can be activated by myriad factors, including growth factors, numerous 
cytokines, JAK, ROS, heat shock proteins and xenobiotics [188]. IL-6 is both upstream and 
downstream of STAT3 activation, and we found that endothelial cells undergoing 10% stretch 
produced increased amounts of this cytokine. This is compatible with prior gene profiling studies 
showing that cyclical stretch increases IL-6 expression in endothelial cells [169]. We found that 
immune-clearing of IL-6 inhibited STAT3 activation and monocyte transformation to the 
intermediate phenotype suggesting a scenario in which IL-6 released by the endothelium 
stimulates STAT3 activation in adjacent monocytes, and ultimately greater amounts of IL-6 
production by these latter cells in a feed-forward fashion. Of note, IL-6 quartiles were found to 
be strongly associated with the risk of developing hypertension in the Nurses Health Study [243], 
and mice lacking this cytokine are protected against Ang II-induced hypertension [244].  
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We also found that PEG-Catalase, which scavenges hydrogen peroxide, prevents monocyte 
transformation and STAT3 activation. This finding is compatible with prior studies showing that 
cyclical stretch activates production of ROS by endothelial cells, initially via activation of the 
NADPH oxidase and subsequently from uncoupled NO synthase [180]. In preliminary studies, 
we confirmed that superoxide production, as measured by detection of 2-hydroxyethidium 
formation from dihydroethidium, was increased in both monocytes and endothelial cells when 
the latter cells were exposed to 10% vs. 5% stretch (data not shown). Our data suggest that 
superoxide is unlikely the mediator of monocyte transformation, as the superoxide dismutase 
mimetic Tempol failed to prevent formation of intermediate cells or STAT3 activation. It is 
therefore likely that hydrogen peroxide, formed by dismutation of superoxide, mediates these 
effects. Hydrogen peroxide is relatively stable and thus likely to serve a paracrine-signaling role 
in mediating cross talk between the endothelium and adjacent monocytes. Of interest, the 
expression of heme oxygenase, which has anti-oxidant properties, inversely correlates with 
monocyte expression of CD14 in humans [245].    
In our experimental setup, we cannot exclude the possibility that IL-6 and hydrogen peroxide 
also have effects on the endothelium. Activation of the IL-6 receptor has been shown to stimulate 
the JAK-STAT pathway that can lead to further IL-6 production [246]. Likewise, hydrogen 
peroxide can activate the NADPH oxidase, which could ultimately lead to additional hydrogen 
peroxide production in a feed forward fashion [247]. We have also shown that ROS released 
from the mitochondria can stimulate the NADPH oxidase in endothelial cells [40]. Thus, 
production of IL-6 and hydrogen peroxide in a milieu of endothelial cells and monocytes could 
have actions on both cell types, but ultimately lead to monocyte differentiation.  
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Another potential mediator of STAT activation is loss of NO signaling. NO has been shown to 
inhibit STAT3 activation in ovarian cancer cells and endothelial NO bioavailability is commonly 
lost in hypertension and related diseases [212, 248]. Monocytes in the circulation are constantly 
exposed to endothelial-derived NO, however when placed in culture, spontaneously acquire 
CD16. We confirmed this in our studies and found that this was associated with STAT3 
phosphorylation and that the NO donor, DETA-NONOate, markedly inhibited monocyte 
transformation and STAT activation. We also found that the addition of L-NAME to HAECs 
undergoing 5% stretch promoted monocyte STAT activation, in a fashion similar to 10% stretch. 
L-NAME exposure did not cause monocyte transformation during this 48 hour exposure, 
suggesting that other signals like IL-6 and hydrogen peroxide might also be needed for this 
response.  
In keeping with our findings in the co-culture experiments, we found that hypertensive humans 
have an increase in circulating intermediate and non-classical monocytes, and that this seems 
dependent on their severity of hypertension. It is likely that this shift in monocyte population 
predisposes to further inflammatory responses, including production of cytokines and T cell 
activation. Of note, we also confirmed that intermediate monocytes of both hypertensive and 
normotensive subjects exhibit STAT1 and STAT3 activation. This is compatible with a scenario 
in which intermediate monocytes consistently exhibit and likely require STAT activation for their 
transformation from the classical precursors, but that this transformation is higher in 
hypertension, perhaps due to encounter with activated endothelium.   
In summary, our current study provides a previously unrecognized link between mechanical 
forces affecting the endothelium and activation of monocytes (Figure 2-15). This provides new 
insight into how the immune system can be activated in hypertension and for the first time 
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implicates intermediate monocytes as potentially important in this disease. Intermediate 
monocytes are not only a biomarker of inflammation in hypertension, but their acquisition of 
CD16 arms these cells to possess cytotoxic function and to produce TNF. The production of 
cytokines like IL-6, IL-23 and IL-1 can also skew T cells to produce IL-17A, which we have 
previously shown to be involved in hypertension [129]. It is therefore likely that altered endothelial 
mechanical forces have important effects on immune cell function, leading to end organ 
dysfunction and worsening hypertension.  
 
Figure 2-15: Model: Increased endothelial stretch promotes monocyte transformation and 
activation. 
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Chapter III 
Interplay between Signal transduction and activation of transcription factors, ROS and 
inflammation during hypertension 
Introduction 
One third of the population in United States has hypertension, and its prevalence increases with 
age. Current treatments for hypertension include ACE inhibitors, β- blocking drugs, calcium-
blocking drugs, and thiazide diuretics [249]. Despite treatment with these agents, up to 20% of 
patients continue to have poorly controlled BP. Recent studies in our laboratory and others have 
shown a critical role of the innate and adaptive immune system in BP elevation caused by 
several stimuli including pro-inflammatory cytokines, Ang II, DOCA-salt hypertension and 
norepinephrine [12]. The vasculature also plays an essential role in hypertension. Ang II 
promotes vascular disease and hypertension partly by formation of pro-inflammatory cytokine 
IL-6. IL-6 is upstream of STAT3 and binds to its receptor on the plasma membrane to initiate the 
JAK/STAT cascade. Johnson et al. found that isolated carotid arteries from WT mice incubated 
with Ang II had increased levels of superoxide and that this was prevented by addition of STAT3 
inhibitors, Stattic or S3I-201 [210]. Further, this group found that Ang II-induced hypertension in 
WT mice was reduced by 40 mmHg in mice treated with S3I-201, confirming a role of STAT3 in 
hypertension. STAT3 can be activated via many mechanisms apart from IL-6/JAK pathways. 
Mitochondrial ROS can promote dimerization of the glycolytic enzyme pyruvate kinase M2 
(PKM2) and this enables nuclear translocation [228]. Nuclear PMK2 acts as a protein kinase 
that phosphorylates nuclear STAT3.  
Reactive oxygen species play a role in the genesis of hypertension. Ang II can activate the 
NADPH oxidase to induce superoxide production, which can lead to endothelial dysfunction and 
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reduction of NO bioavailability. Dikalov et al. showed that depletion of NOX2, but not NOX1, 
NOX4, or NOX5 inhibits Ang II-induced superoxide production [250]. This group found that 
NOX2 knockout mice (NOX2-/-) displayed blunted Ang II-induced hypertension and the 
superoxide production associated with it. NO is a vasodilator and essential for normal endothelial 
functionality. Inhibition of NO results in severe hypertension and renal vasoconstriction [181]. 
Our group found that aortas from mice exposed to DOCA-salt hypertension had increased ROS 
production by NO synthase and tetrahydrobiopterin oxidation, which leads to reduction of NO 
bioavailability [51]. Conversely, treatment with oral tetrahydrobiopterin to DOCA-salt infused 
mice leads to a reduction of vascular ROS and an increase in NO production. NO also plays a 
role in STAT3 activation. Kielbik et al. found that addition of NO donor, DETA NONOate, to 
ovarian cancer cells inhibits STAT3 and AKT3 phosphorylation and downregulated their 
cytosolic levels [212]. These data suggest that NO plays a role in STAT3 signaling and that this 
process could be evident in hypertension.  
An emerging paradigm is that activated immune cells enter the kidney and blood vessels and 
release cytokines that cause renal and vascular dysfunction [137]. Work from our laboratory has 
established a critical role of DCs in hypertension. We showed that either blockade or genetic 
deletion of B7 ligands on antigen presenting cells such as DCs that are essential for T cell 
signaling reduces blood pressure [138]. In addition, we showed that Ang II-induced hypertension 
causes a 5-fold increase in superoxide production in DCs [139]. A major finding in this study is 
that this leads to formation of IsoLG, which rapidly ligate lysines on proteins. These IsoLG-
protein adducts accumulate in DCs of hypertensive mice and in monocytes of hypertensive 
humans [139]. Another stimulus of immune activation in hypertension is increased sodium. We 
found that DCs exposed to high concentrations of sodium have increased levels of ROS and 
82 
 
IsoLG-adducts and they are able to induce T cell proliferation [149]. Recently, we have identified 
that monocyte-derived DCs (CD11b+CD11c+MHC-II+) have the highest accumulation of these 
IsoLG-adducts and are more pro-inflammatory having the ability to promote T cell proliferation 
in comparison to other DC subsets. 
In this study, we examined the role of STAT3 in hypertension in vivo. As we have previously 
shown in Chapter II, increased endothelial stretch promotes human monocyte activation and 
transformation into the intermediate monocytes and the CD209 DC-like cells. We showed that 
this process occurs via STAT3 and, thus, in this chapter we sought to determine whether this is 
true using various mouse models. In this study, we also determined the role of hematopoietic 
and somatic NOX2 in hypertension and STAT3 activation in response to Ang II treatment. 
Therefore, this study gives insight into the potential role of dendritic cell STAT3 and NOX2 in the 
genesis of hypertension.         
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Materials and Methods 
Animals 
Mouse Strains: WT C57Bl/6 mice, WT SJL CD45.1 mice, tgCRE/CD11C mice, STAT3loxp/loxp mice 
and NOX2-/- mice were obtained from The Jackson Laboratory, Bar Harbor, ME, USA. 
STAT3/CD11c KO mice were made by crossing STAT3loxp/loxp with tgCRE/CD11C mice. The resultant 
offspring were heterozygotic for loxP sites and for these were crossed to create mice that were 
homozygotic for STAT3loxp/loxp genotype. Male mice of approximately 10-12 weeks of age were 
used.   
All animal procedures were approved by Vanderbilt University’s Institutional Animal Care and 
Use Committee (IACUC) where the mice were housed and cared for in accordance with the 
Guide for the Care and Use of Laboratory Animals, US Department of Health and Human 
Services.   
Surgical Procedures and Blood Pressure Measurements 
Angiotensin II infusion: Mice were anesthetized with 1% isoflurane in 100% oxygen in a 
specialized anesthetizing chamber. Two week osmotic mini-pumps were implanted 
subcutaneously in mice to infuse high-dose Ang II (490 ng/kg/min) or vehicle (sham, 0.08 M 
sodium chloride/1% acetic acid solution) for 6 to 14 days (Alzet, Model 2002; DURECT 
Corporation, Cupertino, CA, USA) as previously described [125, 139].   
Tail Cuff Blood Pressure Measurements: This method of blood pressure measurement is non-
invasive. For these measurements, we used the MC4000 Blood Pressure Analysis System 
(Hatteras Instruments). The person performing the blood pressure measurement was blinded 
for the genotype and treatment of the animal. Four mice were placed on pre-warmed platforms, 
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which promotes vasodilation of the tail artery. A magnetic black cover was used to cover the 
mice and tails from mice were threaded through a small blood pressure cuff and gently taped 
down. The machine measures systolic blood pressure in cycles of 10 and gives an average. To 
allow the mice to acclimate to this device, the first two rounds of 10 cycles are eliminated from 
the analysis and rounds 3 and 4 are averaged together to generate a final systolic blood pressure 
value for the day. The blood pressure of the mice is measured two days per week and averaged 
to produce a final weekly value [13].    
Carotid Radiotelemetry Blood Pressure Measurement: This method of blood pressure 
measurement is invasive. Mice were anesthetized with ketamine/xylazine (90-120 mg/kg + 10 
mg/kg; 1:1 volume ratio). The catheter that is connected to the transducer was inserted into the 
isolated left common carotid artery and advanced until the tip was inside the thoracic aorta. The 
transmitter was then positioned under the skin on the right flank close to the hind limb [139]. 
After telemetry implantation, mice were allowed 10 days to recover prior to baseline 
measurements followed by the implantation of osmotic mini-pumps as described above. 
Measurements of blood pressure were obtained daily or three consecutive days per week for a 
total of three weeks.   
Stattic treatment in mice: Animals were administered vehicle or Stattic (5 mg/mL) every two days 
by oral gavage. Stattic treatment began two days before initial administration of Ang II and 
continued through the rest of Ang II treatment (14 days).  
Euthanasia of mice: All mice were sacrificed at the end of each experiment by CO2 inhalation. 
Organs were transcardially perfused by physiological pressure with saline solution prior to organ 
collection.  
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Measurement of Vascular Reactivity  
Third-order mouse mesenteric arterioles were dissected free of perivascular fat and 2 mm 
segments were used to perform isometric tension studies. Studies were performed in a small 
vessel horizontal wire myograph (Danish Myo Technology, models 610M and 620M) with a 
physiological salt solution (130 mM NaCl, 4.7 mM KCL, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 
mM NaHCO3, 5 mM glucose and 1.6 mM CaCl2). LabChart Pro v7.3.7 (AD Instruments) was 
used to record isometric tone for each vessel. Vessels were equilibrated over a 20 minute period 
at 37°C. To determine optimal passive tension to simulate an in vivo transmural pressure of 100 
mmHg, a passive circumference-tension curve was generated for each vessel [251]. 
Endothelium-dependent and endotheluml-independent vascular relaxations were tested using 
increasing concentrations of acetylcholine or sodium nitroprusside, respectively, following pre-
constriction with norepinephrine (10 µM).    
Flow Cytometry 
Flow cytometry for mice tissues: Single cell suspensions were prepared from aortas, kidneys, 
spleen and mesenteric lymph nodes as previously described [153]. Single cell suspensions of 
thoracic aorta with surrounding perivascular fat were digested using RPMI 1640, 5% FBS, 
Collagenase A (1mg/mL), Collagenase B (1 mg/1mL) and DNase I (0.1 mg/mL). Aortas were 
homogenized by hand in 1.5 mL Eppendorf tubes using scissors and incubated in rotator at 37°C 
for 30 minutes [44]. Tissue homogenates were filtered through a 40 µM cell strainer after 
digestion. Kidneys were placed in digestion media containing RPMI 1640, 5% FBS, Collagenase 
D (2mg/mL) and DNase I (0.1 mg/mL) and homogenized using AutoMACS Dissociator (Miltenyi 
Biotech). Homogenized tissues were incubated and shaking at 37°C for 20 minutes. Single cell 
suspensions were stained for flow cytometry using the following antibodies: Pacific 
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LIVE/DEAD™ Fixable Violet Dead Cell Stain (Life Technologies); APC-CY7-conjugated anti-
F4/80 (Biolegend); AmCyan-conjugated CD11b; AmCyan-conjugated Ly6C (Biolegend); FITC-
conjugated CD44 (BD Bioscience); APC-conjugated CD4 (Biolegend); PE-conjugated CD8a 
(Biolegend); AmCyan-conjugated CD45 (Biolegend); PE-conjugated anti-MerTK; PerCPCy5.5-
conjugated anti-MHC-II; PECy7-conjugated anti-CD64; FITC-conjugated anti-CD11c 
(Biolegend); AmCyan-conjugated anti-CD45.1 (BD Bioscience) and anti-CD45.2 (BioLegend). A 
known quantity (50 µL) of calibration or counting beads (123count eBeads, eBioscience) was 
added to each sample prior to analysis. BD FACSCanto II system was used to run the samples 
and FlowJo® was used for data analysis. Gates were set using FMO controls. Results were 
normalized using bead count and expressed as number of cells per kidney, spleen, lymph nodes 
or per thoracic aorta.  
Intracellular staining for phosphorylated STAT3 and Isolevuglandin-adducts: Murine cells were 
washed and stained first with Pacific LIVE/DEAD™ Fixable Violet Dead Cell Stain (Life 
Technologies). Mouse single cell suspensions were then washed and stained with indicated 
surface antibodies (described above) for 15 minutes at 4°C. Cells were immediately fixed and 
permeabilized after staining with FIX & PERM® Cell Fixation & Permeabilization Kit 
(ThermoFisher) by adding 100 µL of Reagent A and incubating for 15 minutes in the dark at 
room temperature. Cells were washed with 3 mLs of wash medium (1XPBS + 0.1% NaN3 + 5% 
FBS). Cells were permeabilized using 100 µL of Reagent B and 3 µLs of APC-conjugated anti-
pSTAT3 (Y705) or 5 µLs of Alexa 488-conjugated anti-D11 ScFv and incubated for 20 minutes 
at room temperature in dark. Cells were washed with 3 mLs of wash medium and resuspended 
in MACS buffer for flow cytometry analysis. Gates were set using FMO controls. Results were 
normalized using bead count and expressed as total number of cells.  
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Western Blotting  
For the following experiments, DCs were isolated from spleens of STAT3/CD11c KO mice and 
STAT3loxp/loxp mice using the positive selection for mice CD11c MicroBeads Ultrapure Kit 
(Miltenyi Biotec). Western blotting were performed as previously described [149], cells were 
lysed in 150 uLs of the lysis buffer solution, 10 mLs of RIPA buffer (Sigma) and one tablet of 
complete Tablets protease inhibitor cocktail (Roche) and one tablet of the PhosSTOP EASYpack 
phosphatase inhibitor cocktail (Roche). Protein was quantified using the Pierce™ BCA Protein 
Assay Kit (ThermoScientific). Protein samples (20 µg) were separated by SDS-PAGE and 
transferred to a nitrocellulose membrane and blocked with 5% milk and 1% BSA in 1X TBS-T as 
previously described [226]. Membranes were probed with primary antibody total STAT3 antibody 
(Cell Signaling). Membranes were labeled using horseradish peroxidase (HRP)-conjugate and 
detected with chemiluminescence solution using the SuperSignal™ West Femto Maximum 
Sensitivity Substrate (Thermo Scientific). Membranes were imaged with a BioRad ChemiDoc 
Imager. Blots were then stripped for 15 minutes and re-probed using an antibody for α-Actin 
(Abcam). Densitometry was performed using the BioRad Image Lab software and bands of 
interest were normalized to α-Actin.  
Bone Marrow Transplants Studies 
Two weeks prior to bone marrow transplant (BMT), 6 to 8 week old NOX2-/- or CD45.1 WT mice 
were transferred to sterile cages and fed sterile chow and acidified water (pH 2.0) containing 1 
mg/ml of sulfamethazine-Na+ (Sigma-Aldrich) and 0.2 mg/ml of trimethoprim (Sigma-Aldrich) for 
prophylaxis. On the day of BMT, mice were lethally irradiated with a dose of 10 Gy 4 hours prior 
to BMT via a 137Cs irradiator (J.L. Shepherd and Associates). Bone marrow (BM) cells were 
isolated from pooled femurs and tibias collected from mice and used to reconstitute the marrows 
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of recipient mice (~20 million cells per mouse). BM cells were transplanted to recipient mice via 
tail vein using a 25-gauge needle and mice were housed for 8 weeks to allow engraftment of the 
BM. Success of engraftment was determined by presence of CD45.1 or CD45.2 using Amcyan-
conjugated anti-CD45.1 antibody (BD Bioscience) and anti-CD45.2 antibody (BioLegend).  
Saline Challenge Study 
Mice underwent a saline challenge and as a result, we examined the ability of mice to excrete 
water and sodium. Urination was stimulated by suprapubic compression. The mice were briefly 
anesthetized with isoflurane and intraperitoneally injected with normal saline using a volume 
equal to 10% of their body weight as previously described [153]. After awakening, mice were 
placed in metabolic cages for 4 hours and the volume-excreted urine was accurately recorded 
and presented as percentage of the volume injected. Sodium concentrations from excreted urine 
were measured with a flame photometer (Eppendorf EFOX 5053).  
Nitric oxide measurements by Electron Spin Resonance   
Mesenteric vessels were isolated and cleaned from any remaining fat. NO levels in vessels were 
quantified by electron spin resonance (ESR) and colloid Fe(DETC)2 as previously described 
[252]. Following a 1 hour incubation, vessels were transferred to a 1 mL insulin syringe and 
snap-frozen in liquid nitrogen. ESR spectra were analyzed by EMX ESR spectrometer (Bruker 
Biospin Corp., Billerica, MA) with super high Q microwave cavity using liquid nitrogen Dewar 
flask (Wilmad-Labglass, Vineland, NJ). ESR settings for NO measurement include: field sweep, 
100 Gauss; microwave frequency, 9.43 GHz; microwave power, 10 milliwatts; modulation 
amplitude, 2 Gauss; conversion time, 70 msec; time constant, 5.24 seconds; scan number, 4 
[253].     
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Statistics   
All data are expressed as mean ± SEM. One tailed- unpaired Student’s t-tests were used to 
compare two groups. When examining the effect of bone marrow transplant from different 
recipients we employed one-way ANOVA with Student Newman Keuls post-hoc test. When 
examining the effect of bone marrow transplant from different recipients on blood pressure we 
employed two-way ANOVA with Student Newman Keuls post-hoc test. To compare telemetry 
blood pressure of STAT3/CD11c KO mice, we employed two-way ANOVA followed by Holm-
Sidak’s multiple comparisons test. To compare tail cuff blood pressure measurements on the 
Stattic treated mice, we employed two-way ANOVA with Student Bonferroni’s post-hoc test. For 
vascular function studies, we employed a two-way ANOVA followed by Holm-Sidak’s multiple 
comparisons test. P values are reported in the figures and were considered significant when less 
than 0.05.  
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Results 
Angiotensin II-induced hypertension in Wildtype C57Bl/6 mice promotes accumulation of 
myeloid cells containing activated STAT3 in the kidney and aorta: In Chapter II, we defined 
some of the factors involved in mechanical stretch of vessels that promote monocyte 
transformation and activation in humans. In subsequent experiments, we sought to determine 
the role of hypertension in vivo on monocyte transformation in mice. We induced hypertension 
in C57Bl/6 WT mice by infusion of Ang II (490 ng/kg/min) for 6 days and analyzed single cell 
suspensions of the kidney, aorta, spleen and periaortic lymph nodes for the presence of 
monocytes, macrophages (MΦ) and DCs using a flow cytometry gating strategy that effectively 
allows discrimination of these cells (Figure 3-1A). We found a significant increase in the total 
number of macrophages (Figure 3-1B) and DCs (Figure 3-1C) and a trend of an increase in the 
monocytes (Figure 3-1D) within the aorta of Ang II treated mice. This increase in cell number 
was accompanied by an increase in STAT3 (Y705) activation (Figure 3-1E-F) and a trend of an 
increase in the monocyte population (Figure 3-1G). We also found an increase in macrophages, 
DCs and monocytes in the Ang II treated mice within the kidneys (Figure 3-1H-J) and an increase 
in STAT3 activation in each of these populations (Figure 3-1K-M). In the lymph nodes, only 
macrophages were increased in response to Ang II infusion (Figure 3-2A), while there was no 
change in DCs or monocytes. We also observed an increase in the STAT3 activation of 
monocytes in the lymph nodes (Figure 3-2B) of Ang II-treated mice. In the spleen, we found no 
major differences in the presence of macrophages or monocytes, but a significant decrease in 
DCs of hypertensive mice (Figure 3-2C). There was also a decrease in STAT3 activation within 
macrophages of spleen from Ang II-treated mice and no differences in the other cell types 
(Figure 3-2D). Further, we found that WT mice after 14 days of Ang II treatment had persistently 
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increased macrophages and DCs (Figure 3-3A) in the aorta accompanied by activation of STAT3 
(Figure3-3B). To determine the location of monocytes infiltrating the aorta after 2 weeks of Ang 
II infusion in C57Bl/6 mice, we performed immunofluorescence of aortic sections for F4/80 (red), 
pSTAT3 (Y705, green) and DAPI. We found that after 2 weeks of Ang II infusion, monocytes 
and macrophages localize in the perivascular fat and adventitia segments of the aorta and these 
co-localize with pSTAT3 (Y705) (Figure 3-4). These data suggest that monocytes, DCs and 
macrophages leave secondary lymphoid organs in response to a hypertensive stimulus and 
accumulate in the vasculature and kidneys, which is associated with the end-organ damage and 
that these have STAT3 activation. 
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Figure 3-1: Angiotensin II-induced hypertension in wildtype C57Bl/6 mice promotes an increase 
in STAT3 phosphorylation in the immune cells from kidney and aorta. A. Representative flow 
cytometry dot plots showing the gating strategy to identify macrophages, DCs and monocytes from 
C57Bl/6 wildtype mice infused with Ang II (490 ng/kg/min) or sham for 6 days. B-D. Mean values of 
absolute numbers of indicated cell types per thoracic aorta. E. Mean values of pSTAT3 (Y) expression 
within the macrophage (Mφ), (F) DC and (G) monocyte populations per thoracic aorta. H-J. Mean values 
of absolute numbers of indicated cell types per kidney. K. Mean values of pSTAT3 (Y) expression within 
the macrophage, (L) DC and (G) monocyte populations per kidney. A total of n=5, sham, and n =7, Ang 
II, treated mice per group were used. One-tail unpaired t-test was employed (*p<0.05, ** p<0.01, *** 
p<0.001).  
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Figure 3-2: Angiotensin II-induced hypertension in wildtype C57 mice and the STAT3 
phosphorylation in the immune cells from lymph nodes and spleen. C57Bl/6 wildtype mice were 
infused with Ang II (490 ng/kg/min) or sham for 6 days. A. Mean values of absolute numbers of indicated 
cell types per periaortic lymph nodes. Mean values of p-STAT3 (Y) expression within the macrophage 
(Mφ), DC and monocyte populations per periaortic lymph nodes. B. Mean values of absolute numbers of 
indicated cell types per spleen. Mean values of p-STAT3 (Y) expression within the macrophage, DC and 
monocyte populations per spleen. Statistical differences were determined using one-tailed unpaired t-
tests (*p<0.05).  
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Figure 3-3: Angiotensin II-induced hypertension in wildtype C57Bl/6 mice promotes an increase 
in STAT3 phosphorylation in the immune cells from kidney and aorta after 14 days. C57Bl/6 
wildtype mice were infused with Ang II (490 ng/kg/min) or sham for 14 days. A. Mean values of absolute 
numbers of macrophages (Mφ), DCs and monocytes per thoracic aorta. B. Mean values of p-STAT3 (Y) 
expression in the indicated cell type. Statistical differences were determined using one-tailed unpaired t-
tests (*p<0.05, **p<0.01, **** p<0.0001).  
 
 
 
Figure 3-4: Monocytes and macrophages from Ang II hypertensive wildtype mice localize to the 
perivascular fat in the aorta and express STAT3. C57BL/6 mice were infused with Ang II (490 
ng/kg/min) or sham for 14 days. Perfusion-fixed sections of the thoracic aortas were sectioned (6 mm) 
and immunofluorescence was performed to stain for F4/80 (red), pSTAT3 (Y705) (green) and 
counterstained with DAPI. Co-localization of F4/80 and pSTAT3 (Y) is shown.  
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Pharmacological STAT3 inhibition in Ang II-treated WT mice: Studies by Johnson et al. have 
shown the importance of STAT3 in the development of hypertension and that inhibition of STAT3 
via treatment with the small molecule inhibitor, S3I-201, blunts the Ang II hypertensive response 
[210]. To determine whether in vivo inhibition of STAT3 will reduce transformation of monocytes 
to DCs and macrophages in hypertensive mice, we sought to inhibit STAT3 in hypertensive WT 
C57Bl/6 mice with the small molecule, Stattic (5 mg/mL). We administered Stattic or vehicle to 
mice by oral gavage every other day starting two days before Ang II infusion and continued 
treatment until mice were sacrificed (14-15 days after initial Ang II infusion). We measured 
systolic BP by tail cuff method and found no differences between Stattic or vehicle treated WT 
mice at baseline, day 7 and day 14 after Ang II infusion (Figure 3-5A). To determine whether 
Stattic-treated mice are protected against the endothelial dysfunction that occurs in response to 
hypertension, we assessed vascular function of resistance vessels by measuring endothelium-
dependent and –independent relaxation of third order mesenteric arterioles from Stattic or 
vehicle-treated mice. Mesenteric arterioles from Stattic and vehicle-treated mice displayed no 
differences in relaxation in response to acetylcholine (Ach) (Figure 3-5B). Endothelium-
independent relaxation in response to sodium nitroprusside (SNP) showed a trend for 
improvement in Stattic-treated mice (Figure 3-5C). However, when we measured the presence 
of monocytes, DCs and macrophages in the aorta of both experimental groups we found no 
differences in the presence of these or the levels of STAT3 activation indicating that treatment 
with Stattic and, thus, inhibition of STAT3 was not successful in these experiments (Figure 3-
5D-E).  
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Figure 3-5: Systemic effects of the in vivo administration of STAT3 inhibitor, Stattic, in wildtype 
mice exposed to Ang II-induced hypertension. WT C57Bl/6 mice were given Stattic (5 mg/mL) or 
vehicle every two days by oral gavage starting two days before Ang II (490 ng/kg/min) infusion for 14 
days. A. Systolic blood pressure measured noninvasively using the tail-cuff method over 14 days of Ang 
II infusion in Stattic- or vehicle-treated WT C56Bl/6 mice (n = 4 and n = 5, respectively). B. Endothelium-
dependent relaxation in response to increasing doses of acetylcholine (Ach) in stattic- or vehicle-treated 
WT mice is shown. C. Endothelium-independent relaxation in response to increasing doses of sodium 
nitroprusside (SNP) is also shown (vehicle, n = 4; stattic, n = 3). D. Mean values of absolute numbers of 
Mφ, DC and monocyte populations per thoracic aorta. E. Mean values of p-STAT3 (Y) expression in the 
indicated cell type (n = 5). Statistical differences were determined using a two-way ANOVA followed by 
Bonferroni’s multiple comparisons test for the tail-cuff experiments; a two-way ANOVA followed by Holm-
Sidak’s multiple comparisons test for the vascular function studies; and one-tailed unpaired t-tests for the 
flow cytometry on the aorta. 
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Effects of STAT3 inhibition in dendritic cells during hypertension: To assess the role of 
STAT3 in dendritic cells during hypertension, we created a knockout (KO) mouse using CRE-
lox technology by crossing a STAT3loxP/loxP floxed mouse with the CD11ctg/CD11cCRE mouse. These 
STAT3/CD11c KO mice should have deletion of STAT3 within CD11c+ cells including DCs, 
activated monocytes and activated macrophages. To confirm the inhibition of STAT3 in these 
mice, we isolated CD11c+ cells from spleen of both STAT3loxP/loxP and STAT3/CD11c KO mice 
using magnetic sorting and extracted protein from these cells to perform Western blot 
techniques. As shown by the blots in Figure 3-6A, STAT3 protein expression was reduced by 5-
fold compared to floxed controls (Figure 3-6B) after protein normalization to α-Actin. These 
STAT3/CD11c KO mice displayed mild colitis associated by presence of rectal prolapse in 75% 
of pups as well as impaired weight gain (Figure 3-6C). We implanted telemeters to measure 
blood pressure in these mice during baseline and two weeks after Ang II infusion. As shown in 
Figure 3-6D, the systolic blood pressure showed no differences at baseline between floxed 
controls and STAT3/CD11c KO mice, but there was a trend of a reduction towards the end of 
the Ang II treatment (> day 10) in the mice with STAT3 deletion in their DCs. There were no 
differences at baseline or after Ang II infusion in the diastolic blood pressure of both experimental 
groups (Figure 3-6E). We proceeded to look at the immune cells present within the aorta, spleen, 
kidney and blood at baseline levels in the STAT3/CD11c KO mice and the floxed controls. We 
found a significant reduction in the number of macrophages and DCs present in the spleen of 
the STAT3/CD11c KO mice accompanied by a reduction in the activation of STAT3 (Y705) in 
the macrophage, DCs and monocytes within this tissue (Figure 3-7A-B). In contrast, in the aorta, 
we found a significant increase in the number of macrophages and monocytes in the KO mice 
and the macrophages had an increase in STAT3 activation (Figure 3-7C-D). There was no 
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difference in the number of immune cells between KO and floxed controls in the kidney and 
blood (data not shown). 
 
Figure 3-6: Effects of genetic deletion of STAT3 in dendritic cells in hypertension. STAT3/CD11c 
KO mice were made by crossing STAT3loxp/loxp with tgCRE/CD11C mice. A. DCs from STAT3/CD11c KO and 
STAT3loxp/loxp mice were isolated from the spleen by CD11c+ magnetic sorting and protein was isolated. 
Western blots for total STAT3 and normalized to α-Actin are shown. B. Normalized expression of STAT3 
in DCs isolated from spleen of STAT3/CD11c KO and STAT3loxp/loxp mice (n = 4). C. Illustrations of rectal 
prolapse in STAT3/CD11c KO mice. D. Systolic blood pressures and (E) diastolic blood pressures using 
carotid radiotelemetry over 14 days of Ang II infusion in STAT3/CD11c KO and STAT3loxp/loxp mice (n = 
6). Statistical comparison were made using unpaired t-tests for the Western blots and two-way ANOVA 
followed by Holm-Sidak’s multiple comparisons test for the telemetry data (*p<0.05).  
99 
 
 
Figure 3-7: Characterization of immune cells and their expression of STAT3 within spleen and 
aorta of STAT3/CD11c KO mice at baseline. STAT3/CD11c KO and STAT3loxp/loxp mice were sacrificed 
for their immune cell characterization by flow cytometry. A. Mean values of absolute numbers of indicated 
cell types per spleen. B. Mean values of p-STAT3 (Y) expression within the Mφ, DC and monocyte 
populations per spleen. C. Mean values of absolute numbers of indicated cell types per thoracic aorta. 
D. Mean values of p-STAT3 (Y) expression within the macrophage, DC and monocyte populations per 
thoracic aortas. Statistical differences were determined using one-tailed unpaired t-tests (*p<0.05, 
**p<0.01, ***p<0.001).  
 
In Chapter II, we found that the presence of NO is crucial for the inhibition of monocyte 
differentiation and activation during hypertensive levels of stretch on vessels. To further 
characterize these KO mice and determine whether NO is altered in their vessels, we proceeded 
to measure NO by ESR in mesenteric arterioles. We found no difference in NO production in 
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STAT3/CD11c KO mice exposed to Ang II hypertension (Figure 3-8A) compared to STAT3 
floxed controls. To determine the effect of DC STAT3 inhibition on renal function, a sodium 
challenge study was performed as previously described [127]. We assessed whether there could 
be a potential shift in the pressure-natriuresis curve by injecting mice intraperitoneally with a 
saline load equal to 10% of their body weight. Mice were then placed in a metabolic chamber for 
4 hours and urine volume and sodium content was measured. STAT3 floxed control mice 
excreted 50% and the STAT3/CD11c KO mice excreted 45% of the initial volume input. There 
were no differences in percent of sodium output in both experimental groups (Figure 3-8B). 
These data indicate that there is no apparent protection from renal damage in the STAT3/CD11c 
KO mice or the controls in response to Ang II hypertension.    
We proceeded to measure the immune cells present in the aorta and kidney of STAT3/CD11c 
KO mice and floxed controls after two weeks of Ang II treatment. We found a trend (P = 0.06) of 
a reduction in the presence of CD11chigh cells within the aorta (Figure 3-8C) and kidney (Figure 
3-8E) of STAT3/CD11c KO mice compared to controls and no differences in macrophages, 
monocytes and Ly6Chigh cells in both tissues. In contrast to this decrease in DCs, there appeared 
to be a compensatory increase in macrophages within the kidney (Figure 3-8E). Further, we 
found a trend of a decrease in STAT3 phosphorylation in Y705 in the CD11chigh cells from the 
aorta (P = 0.1) (Figure 3-8D) and kidney (P = 0.08) (Figure 3-8F). There were no differences in 
STAT3 phosphorylation in the other cell populations of the aorta and kidney. These data indicate 
that even after STAT3 deletion in the DCs, the few cells that remain to be positive for STAT3 
can activate in response to Ang II and mobilize to secondary lymphoid organs.  
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Figure 3-8: Characterization of alteration in vascular NO, renal function and immune cells in the 
kidney and aorta of STAT3/CD11c KO mice after Ang II induced-hypertension. A. Mesenteric 
vessels were isolated from guts of STAT3/CD11c KO and STAT3loxp/loxp mice after 14 days of Ang II 
infusion. NO levels in vessels were quantified by ESR and colloid Fe (DETC)2 and normalized per 
mg of tissue (control, n = 3; KO, n = 7). B. Renal function was assessed by injecting mice intraperitoneally 
with a saline load equal to 10% body weight and determining urine volume and sodium excretion over 
the enduing 4 hours using a metabolic chamber (n = 5), this equals the ratio of % sodium excretion. C. 
Flow cytometry was performed to characterize immune cells. Mean values of absolute numbers of 
CD11chigh DCs, Mφs, LY6Chigh cells and monocytes per thoracic aorta are shown. D. Mean values of p-
STAT3 (Y) expression within these populations is shown. E. Mean values of absolute numbers of 
CD11chigh DCs, Mφs, LY6Chigh cells and monocytes per kidney. F. Mean values of p-STAT3 (Y) 
expression within these populations is shown (control, n = 10; KO, n = 8). Statistical comparisons were 
made using unpaired t-tests.  
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NOX2 in hematopoietic cells is important for the hypertensive response and STAT3 
activation in DCs: Components of the NADPH oxidase system are upregulated by hypertensive 
stimuli and inhibition of these components protect mice from both Ang II and DOCA-salt 
hypertension [56]. Hypertension is associated with increased ROS production by multiple organs 
and elevated vascular ROS promotes the development of hypertension in various animal 
models, including Ang II-induced, DOCA-salt hypertension [56-58], Dahl salt-sensitive 
hypertension and SHR rats [59-61]. NOX2, a component of the NADPH oxidase also known as 
gp91phox, was originally discovered in phagocytes, but now it has been identified in multiple cells 
including endothelial cells, the tubular cells of the kidney and monocytic cells [34]. Dikalov et al. 
showed that depletion of NOX2, but not NOX1, NOX4, or NOX5 inhibits Ang II-induced 
superoxide production [250]. Dikalov et al. and our group has shown that NOX2 knockout mice 
(NOX2-/-) display blunted Ang II-induced hypertension and the superoxide production associated 
with it.  
We sought to determine whether deletion of NOX2 in hematopoietic cells of mice would reduce 
blood pressure and the transformation of monocytes to DCs and macrophages in addition to 
activation of STAT3 in response to Ang II hypertension. We performed BMT experiments to 
determine the source of NOX2 that is relevant to hypertension and measured their BP by 
radiotelemeter implants. WT mice given WT bone marrow developed severe hypertension after 
2 weeks of Ang II infusion (Figure 3-9A). NOX2 deficient mice that received WT bone marrow 
had intermediate systolic blood pressure. In contrast, WT mice that received NOX2-deficient 
bone marrow were markedly protected against the effects of Ang II hypertension. These data 
are compatible with the concept that NOX2 in hematopoietic cells plays a very important role in 
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hypertension. There was a similar trend in the diastolic blood pressure, but it did not reach 
significance (Figure 3-9B).  
We proceeded to characterize immune cells of BMT recipient mice in the aorta, kidney and 
spleen after two weeks of Ang II infusion. We found that mice lacking NOX2 in the somatic cells 
had a striking decrease in monocytes and macrophages in the aorta (Figure 3-9C-D). This is 
compatible with the scenario that chemokines and vascular adhesion molecules released by the 
vessels are redox sensitive. In contrast, these cells still accumulated in the vessels when NOX2 
was deleted in the hematopoietic cells (Figure 3-9C-D). The kidney did not exhibit this pattern of 
altered immune cell infiltration suggesting that different mechanisms might guide renal and 
vascular inflammation (Figure 3-9E-F). We also found that NOX2 deficient DCs in the spleen 
exhibited a reduction in the presence of DCs as well as a lower STAT3 activation and IsoLG 
adduct formation (Figure 3-9G) compared to DCs with a functional NOX2. This scenario is 
compatible with the concept that hydrogen peroxide can modulate STAT3 activation (see 
Chapter II) and that ROS promote formation of IsoLG adducts [139].   
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Figure 3-9: Bone marrow transplant studies to determine the relative role of hematopoietic versus 
somatic NOX2 in Ang II induced hypertension. BMT was performed using NOX2-/- (CD45.2) and WT 
SJL (CD45.1) mice as either donors or recipients as indicated. Three groups were designated (donor: 
recipient): C:C (WT to WT, control group) and C:N (WT to NOX2-/-) and N:C (NOX2-/- to WT) as chimeric 
groups. A. Telemetry recordings of systolic blood pressure and (B) diastolic blood pressure at baseline 
and during 14 days of Ang II infusion (490 ng/kg/min) (C:N, n = 6; N:C, n = 5; C:C, n = 4). C. Quantification 
of flow cytometry for total of macrophages and (D) monocytes per thoracic aorta (C:N, n = 7; N:C, n = 7; 
C:C, n = 4). E. Mean values of absolute numbers of macrophages and (F) monocytes per kidneys (C:N, 
n = 8; N:C, n = 7; C:C, n = 4). G. Mean values of absolute numbers of DCs and expression of p-STAT3 
(Y) and IsoLG-adducts within the DCs per spleen (C:N, n = 7; N:C, n = 7; C:C, n = 4). Statistical 
comparisons were made using a two-way ANOVA followed by the Newman-Keuls multiple comparisons 
test for the telemetry data and one-way ANOVA followed by the Newman-Keuls multiple comparisons 
test  for the flow cytometry analysis (*p<0.05, **p<0.01, ***p<0.001).   
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Discussion 
In this study, we demonstrate that tissue infiltrating monocytes, macrophages and DCs exhibited 
an increase in phosphorylated STAT3 at day 6 and day 14 after Ang II infusion, specifically in 
aorta and kidney. We created a CRE-lox mouse that had STAT3 deleted in their CD11c+ DCs. 
These STAT3/CD11c KO mice showed a trend of a reduction in systolic BP compared to STAT3 
floxed controls. Finally, we found that bone marrow transplantation from NOX2-/- mice into WT 
mice lowered systolic BP compared to NOX2-/- mice that received WT bone marrow. WT mice 
with NOX2-/- bone marrow also had a reduction in STAT3 phosphorylation and IsoLG-adducts 
in DCs from the spleen. These data suggest that NOX2 in hematopoietic cells promotes 
hypertension in part by activating STAT3 and these data are compatible with studies I performed 
in Chapter II showing that hydrogen peroxide likely plays a role in the development of 
hypertension.  
In initial experiments to examine the role of STAT3 in vivo, we treated WT mice with Ang II for 6 
and 14 days. At this time, we found a striking increase in infiltrating monocytes, macrophages 
and DCs in the aorta and kidneys compared to sham-infused animals. These cells consistently 
showed activation of STAT3. Further, STAT3 activation in these immune cells persisted following 
two weeks of Ang II infusion in aorta, thus, STAT3 activation appears early in hypertension. The 
site of this immune infiltration was located in the periovascular fat and adventitia. This is 
compatible with findings from our laboratory that the media is largely spared from these 
inflammatory cytokines [7] .  
In an effort to demonstrate the role of STAT3 in vivo in hypertension, I used two approaches. In 
the first, I administered the small molecule, Stattic, to mice during Ang II infusion. This dose and 
mode of administration of Stattic was based on a prior study, which the drug was used to treat 
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head and neck cancer [254]. In our study, Stattic was not effective in reducing the hypertension 
caused by Ang II, improving vascular function, or surprisingly preventing STAT3 activation. 
Moreover, treatment with Stattic was not effective in preventing immune activation in vivo. The 
reason for this lack of effect of Stattic might be due to either inadequate dosing, mode of 
administration, or off-target effects that lead to toxicity. With regard to the last point, we found 
that approximately 30% of mice treated with Stattic did not survive two weeks of administration. 
It is therefore unlikely that increasing the dose of Stattic would have been beneficial. These 
results differ from those of Johnson et al. who used another small molecule inhibitor of STAT3, 
S31-201, which prevented Ang II-induced hypertension [210]. Future studies using S31-201 
might prove informative in probing the role of STAT3 in hypertension and related disorders.   
The second approach I used to address STAT3 in vivo was to delete STAT3 in DCs using CRE-
lox technology. I found that this led to a slight reduction of blood pressure, which did not reach 
statistical significance. Moreover, deletion of STAT3 in DCs markedly reduced the number of 
DCs in the spleen. Disappointingly, I found that the STAT3 positive DCs were not significantly 
reduced in either the aorta or the kidney after Ang II infusion. Further, there was no reduction of 
infiltration of other immune cells including monocytes and macrophages in these organs. These 
data are compatible with the concept that STAT3 in necessary for DC formation [229], but the 
few cells remaining after STAT3 deletion can be mobilized to secondary lymphoid organs such 
as aorta and kidney upon exposure to Ang II. Importantly, the STAT3/CD11c KO mice displayed 
poor weight gain and exhibited rectal prolapse similar to that previously reported [255]. During 
attempts to perform telemetry implantation and Ang II infusion, approximately 50% of 
STAT3/CD11c KO mice died. Given the high mortality and morbidity of STAT3 deletion in DCs, 
it is difficult to make conclusions regarding the roles of STAT3 in hypertension using this model. 
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In Chapter II, I showed that hydrogen peroxide plays a role in the activation of STAT3. A major 
source of ROS is the NADPH oxidase. Moreover, mice lacking various components of the 
NADPH oxidase are protected against hypertension. However, the relative role of hematopoietic 
vs somatic cell NADPH oxidase roles have not been previously defined. In the current studies, I 
preformed additional experiments to dissect the relative contribution of NADPH oxidase in 
hematopoietic cells vs somatic cells in STAT3 activation, immune infiltration and hypertension. 
To accomplish this, I transplanted NOX2 deficient bone marrow into WT mice and vice versa. I 
also preformed WT to WT bone marrow transplantation as a control. We found that NOX2 in 
hematopoietic cells seems to have a major role in hypertension. WT mice receiving NOX2 
deficient bone marrow were protected from elevation of blood pressure during Ang II infusion. In 
contrast, NOX2 deficient mice that received WT bone marrow had an intermediate phenotype of 
hypertension. In the spleen, WT mice that received NOX2 deficient hematopoietic cells had a 
reduction in the presence of DCs similar to that observed in the STAT3/CD11c KO mice 
accompanied by a reduction in STAT3 activation and IsoLG-adduct formation confirming the role 
of NOX2 in this process as previously described [139]. A striking finding in these mice was that 
there was a marked reduction of macrophage and monocytes infiltration in the vessel wall 
suggesting a role of tissue NOX2 in promoting recruitment of monocytes and macrophages. This 
is compatible with the concept that the transcription of adhesion molecules and chemokines 
involved in monocyte trafficking is redox sensitive [256, 257]. In contrast to the aorta, there was 
no reduction in monocyte/macrophage recruitment to the kidney suggesting that there are 
different modulators on vascular and renal infiltration.  
In this chapter, we sought to determine the role of STAT3 in hypertension using an in vivo 
approach. We found that immune cells infiltrating secondary lymphoid organs after Ang II 
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hypertension have activation of STAT3. Further, we found that NOX2 in hematopoietic cells 
plays a role in the activation of STAT3 and formation of IsoLG adducts, which contribute to the 
immune activation that occurs in hypertension. These findings give insight into the potential role 
of ROS, in particular, hydrogen peroxide and the activation of STAT3 in immune cells, which 
could lead to monocyte activation and transformation similar to our findings in Chapter II.   
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Chapter IV 
Generation of human induced pluripotent stem cells for their differentiation into 
endothelial cells 
Introduction 
In Chapter II, I established a novel method to study human monocytes and identified a new 
mechanism on how they can become activated in hypertension. Monocytes are pleotropic subset 
of leukocytes that are capable of giving rise to a variety of cells relative to the cardiovascular 
system including DCs, macrophages and even collagen-forming cells referred to as fibrocytes. 
Previously, it was thought that monocytes had to transform into DCs or macrophages in order to 
present antigen. However, recent studies have shown that monocytes can enter tissues and 
reemerge with minimal differentiation. While in tissues, these monocytes can take up “non-self” 
antigens and can transport and present these to T cells within secondary lymphoid organs such 
as lymph nodes and spleen [94]. These could be foreign antigens from bacteria, viruses or could 
be modified self-proteins sometimes referred to as neo-antigens. Thus, in studying the ability of 
monocytes to activate T cells, it would be ideal if all the cells present in a model such as mine 
i.e. monocytes, endothelial cells and T cells were from the same donors.  
Thus, in experiments described in this chapter, I sought to establish an experimental model in 
which I can derive endothelial cells from PBMCs of our monocyte donors using the method of 
induced pluripotent stem cells (iPSCs). The ultimate goal of this experimental endeavor was to 
determine the propensity of endothelial cells and monocytes from the same subject to interact 
and produce an immune response. Ultimately this could be used to characterize the propensity 
of an individual to develop immune activation in hypertension.   
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Materials and Methods 
Human subjects 
We performed studies in which we included male and female normotensive participants who had 
blood pressures less than 135/80 mmHg. Normal volunteers were included between ages 18-
55.   
Exclusion criteria included the following: 1) Autoimmune disease or history of inflammatory 
diseases; 2) Recent vaccinations, within the last 3 months; 3) Confirmed or suspected causes 
of secondary hypertension; 4) Severe psychiatric disorder; 5) HIV/AIDS; 6) Current treatment 
with steroids or antihistamines; 7) Liver or renal disease and 8) History of cancer. This was 
approved by the Vanderbilt Institutional Review Board and conformed to standards of the US 
Federal Policy for the Protection of Human Subjects.  
Human aortic endothelial cells  
HAECs (Lonza, Walkersville, MD, USA) were plated on T-75 plates with an initial passage of 4 
and fed every other day with EBM-2 medium (Lonza) containing EGM-2 growth factors and 
supplements (Lonza) and 2% fetal bovine serum (FBS) or Vascular Cell Basal Medium (ATCC®) 
with Endothelial Cell Growth Kit-VEGF (ATCC® PCS-100-041) and 5% anti-anti (100X, Gibco). 
Once cells reached 100% confluency, they were split with 0.25% Trypsin-EDTA (1X) (Gibco) 
and cultures were kept in 37°C incubators with 5% CO2.  
Monocyte isolation and monocyte-human aortic endothelial cells cultures 
HAECs (Lonza, Walkersville, MD, USA) were grown to confluency on flexible 6-well culture 
plates that permit uniaxial stretch (Flexcell® International Corporation, Burlington, NC, USA). 
These were coated with collagen I and 1% gelatin cross-linked with 0.05% of glutaraldehyde.  
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Peripheral blood mononuclear cells were isolated from blood by Ficoll-density gradient 
centrifugation. CD14+ monocytes were further isolated from PBMCs using negative selection 
with the monocyte isolation kit (Miltenyi Biotec 130-096-537; Miltenyi Biotec, Auburn, CA, USA) 
as previously described [149]. Monocyte purity was confirmed by flow cytometry using an anti-
CD14 conjugated antibody and an 80% or higher purity was considered viable for experimental 
purposes. Monocytes from each volunteer were added to the endothelial cells previously grown 
on Uniflex® 6-well culture plates so that we could simultaneous examine the response of one 
million monocytes to endothelial cells undergoing 5% and 10% uniaxial stretch.  
Fluorescence-activated cell sorting and T cell proliferation assay in human cells 
Monocyte populations were collected from the endothelial cells co-culture by including the cells 
in suspension and those that adhered to the endothelium. Adhered monocytes and endothelial 
cells were released in suspension by digesting the collagen I and 1% gelatin coating with 
Collagenase A (1 mg/ml, Roche), Collagenase B (1 mg/mL, Roche) and DNase I (0.1 mg/mL, 
Sigma) in RPMI 1640 medium with 10% FBS for 30 minutes at 37°C. Single cell suspensions 
were stained for PerCPCy5.5-conjugated anti-CD31 and DAPI (Biolegend) and fluorescence-
activated cell sorting (FACS) was used to sort out the CD31+ ECs and select for the remaining 
monocyte populations using BD FACSAria III instrument (Flow Cytometry Shared Resources, 
Vanderbilt University). Two days later, the same patients were recruited to draw blood for pan T 
cell isolation (Miltenyi) from the PBMCs by magnetic labeling and sorting. These T cells were 
pre-labeled with carboxyfluorescein succinimidyl ester (CFSE) cell proliferation kit (Invitrogen) 
and cultured with the FACS sorted CD31- cell populations at a 1:10 ratio (monocyte: T cell) for 
7 days. Proliferation was measured by the CFSE dilution using flow cytometry  
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Human-induced pluripotent stem cell generation  
PBMCs were isolated by Ficoll-density gradient centrifugation from blood of healthy 
normotensive volunteers as described in Chapter II. We used the CytoTune® -iPS 2.0 Sendai 
Reprogramming Kit under feeder-free conditions (Gibco by Life Technologies) to create our 
human iPSC colonies as previously described [258]. Four days before transduction of virus, 
isolated PBMCs were seeded in complete PBMC medium (complete StemPro®-34 serum-free 
medium), in which we added fresh cytokines every day including SCF (100 ng/mL), FLT-3 (100 
ng/mL), IL-3 (20 ng/mL) and IL-6 (20 ng/mL).  Again, we changed the media daily carefully 
without disturbing the cells. At the day of virus transduction, we counted the cells and performed 
transductions in live cells at approximately 300,000 cells per sample. We proceeded to add the 
Klf4, Oct4, and Sox2 (KOS) virus and the c-Myc virus at a multiplicity of infection (MOI) of 5 
(KOS MOI = 5, c-Myc MOI = 5) and the Klf4 virus at an MOI of 3 (hKlf4 MOI = 3) in a total volume 
of 1 mL. By placing a Parafilm® sealing film, we proceeded to centrifuge the samples at 2250 
rpm for 30 minutes at room temperature. Following this step, we resuspended the pellet medium 
containing the virus and an additional 1 mL of complete PBMC media. The following day we 
harvested the cells containing the virus and removed the virus by centrifuging the cells at 200 g 
for 10 minutes and aspirating supernatant. We cultured the live cells in complete PBMC media 
for 2 days. Next, we seeded the live cells in previously coated Geltrex® matrix (ThermoFisher) 
and cultured these in complete StemPro®-34 medium without the cytokines. On day 3 to 6 after 
viral transduction, we replaced media every other day with the same media they were seeded in 
without disturbing the cells. On day 7 after transduction, we began to transition to the Essential 
8® medium (ThermoFisher) by removing half of the StemPro®-34 medium and adding the 
removed volume of this new media. Twenty-four hours later, we replaced the entire media to the 
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Essential 8® medium and continued to replace media every day for the next 21 days. We also 
observed the cells and looked for the emergence of cell clumps, which indicate transformation. 
Day 15 to 21 after transduction, colonies grew to an appropriate size for transferring. Fully grown 
colonies were manually picked and transferred to a Geltrex® matrix coated 12-well plates 
according to manufacturer’s instructions. These experiments were performed in a specialized 
facility for iPSC culture and differentiation.  
Differentiation of human iPSCs from PBMCs into endothelial cells 
For differentiation, human iPSCs were dissociated using StemPro Accutase (ThermoFisher) and 
plated on growth factor-reduced Matrigel (BD Biosciences) at a density of 37,00 to 47,000 cells 
cm-2 in mTeSR1 media (STEMCELL Technologies) with 10 µM ROCK inhibitor Y-27632 
(Calbiochem). Twenty-four hours later, the medium was replaced with Priming Medium, which 
consists of N2B27 medium [1:1 mixture of DMEM:F12 (1:1) with Glutamax and Neurobasal 
media supplemented with N2 and B27 (all from Life Technologies)] with 1 µM CP21R7 (Roche), 
a GSK3 inhibitor, and 25 ng/Ml of BMP4 (R&D Systems). Three days later, this priming medium 
was replaced with endothelial cell Induction Medium consisting of StemPro-34® SFM medium 
(Life Technologies) supplemented with 200 ng/mL VEGF (Miltenyi Biotech) and 2 µM forskolin 
(Sigma-Aldrich) to induce differentiation of iPSCs into endothelial cells. The following day the 
Induction Medium was renewed. On day six of differentiation, the endothelial cells were 
dissociated with StemPro Accutase (ThermoFisher) and selected by magnetic sorting using the 
CD31 microbeads kit (Miltenyi Biotech).   
Flow cytometry 
T cell proliferation study: Monocyte/T cell co-cultures were harvested and single cell 
suspensions were stained for flow cytometry analyses using the following directly conjugated 
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antibodies including: PerCPCy5.5-conjugated 7-AAD viability staining solution (eBioscience), 
Pacific Blue-conjugated anti-CD3 (BioLegend), PECy7-conjugated anti-CD8 (BioLegend), and 
APC Cy7-conjugated anti-CD4 (BioLegend). BD FACSCanto II system was used to run the 
samples and number of proliferated T cells were calculated and averaged using the FlowJo® 
software. Gates were set using FMO controls.    
Characterization of human-iPSCs-derived endothelial cells: Single cell suspensions were 
stained for flow cytometry analyses using the following directly conjugated antibodies including: 
Pacific LIVE/DEAD™ Fixable Violet Dead Cell Stain (Life Technologies), PE-conjugated anti-
VE-Cadherin (BioLegend) and PerCPCY5.5-conjugated anti-CD31 (BioLegend). BD 
FACSCanto II system was used to run the samples and FlowJo® was used for data analysis. 
Gates were set using FMO controls.  
Statistics   
All data are expressed as mean ± SEM. One tailed- paired Student’s t-tests were used to 
compare the number of proliferated T cells cultured with monocytes exposed to endothelial cells 
undergoing 5% vs 10% stretch. P values are reported in the figures and were considered 
significant when less than 0.05.  
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Results  
Monocytes exposed to endothelial hypertensive stretch are capable of promoting T cell 
proliferation: In Chapter II, we described a mechanism in which monocytes can become 
activated and transform to different subset of cells when cultured with endothelial cells 
undergoing hypertensive stretch. Further, it has been reported that monocytes can enter tissues 
and re-emerge into the circulation without differentiation into macrophages or dendritic cells [94]. 
These cells can transport antigen to lymph nodes and have enhanced ability to drive T cell 
proliferation. To determine if endothelial stretch conveys this property to monocytes, we obtained 
T cells from the same monocyte donors after their monocytes had been exposed to endothelial 
cell stretch for 48 hours. These autologous T cells were labeled with CFSE and co-cultured with 
monocytes for 7 days and their proliferation was examined by CFSE dilution. These methods 
are illustrated by Figure 4-1A. Following the gating strategy shown in Figure 4-1B, we measured 
proliferation within the CD4+ and CD8+ T cells. As shown in Figure 4-1C, monocytes previously 
exposed to 10% stretched endothelial cells for 48 hours exhibited an enhanced ability to drive 
CD4+ and CD8+ T cell proliferation as compared to the cells from the 5% stretched endothelial 
cell cultures. After quantification of these cells, both CD4+ and CD8+ T cells significantly 
proliferated when cultured with monocytes exposed to endothelial cells undergoing 10% stretch 
(Figure 4-1D).   
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Figure 4-1: Increased endothelial stretch primes human monocytes to induce T cell proliferation. 
A. Monocyte-HAECs cultures were stretched to either 5% or 10% for 48 hours followed by sorting 
monocytes from HAECs using CD31+ isolation kit and FACS. Monocyte populations were cultured with 
CFSE-labeled T cells isolated from PBMCs of the same participants. Seven days later, we measured 
proliferation in the CD4
+
 and CD8
+
 T cell populations by flow cytometry. B. Flow cytometry gating 
representatives showing live cells, CD3+ T cells and CD4+ and CD8+ T cells. C. Histogram representatives 
for number of proliferated CD4+ and CD8+ T cells. D. Changes in number of proliferated CD4
+
 and CD8
+
 
T cells after 7 days in culture for each subject are depicted by connected lines (n = 7). Comparisons were 
made using one-tail paired t-tests (*p<0.05).  
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Generation of human induced-pluripotent stem cells and differentiation to endothelial 
cells: In Chapter II and the T cell proliferation experiment mentioned above, we used 
commercially purchased HAECs derived from individuals different from our monocyte donors. 
To create an environment in which autologous cells were used, we attempted to differentiate 
human iPSCs into endothelial cells from our PBMC donors. We proceeded to create iPSC 
colonies by dedifferentiating freshly isolated PBMCs from blood of our human volunteers. Using 
the CytoTune®-iPS 2.0 Sendai Reprogramming kit, described in more detail in the methods, we 
introduced Sox2, Oct4, Klf4 and c-Myc to the somatic cells. We were able to grow full-sized iPSC 
colonies. We manually picked these colonies and cultured these in Geltrex® matrix-coated 
plates until we acquired more colonies and performed up to 6 passages from the original colony. 
We were able to confirm the iPSCs by immunofluorescence and the presence of Tra160, an 
iPSC specific protein as illustrated in Figure 4-2.  
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Figure 4-2: Characterization of human induced-pluripotent stem cell colonies. PBMCs were 
isolated from normal human volunteers and subjected to de-differentiation and transformation into iPSC 
colonies by introducing Sox2, Oct4, Klf4 and c-Myc genes. A. Immunofluorescence for the iPSC specific 
protein Tra160 was performed in participant 1 passage 4, (B) participant 1 passage 5, and (C) participant 
3 passage 6. DAPI was used to counterstain the nucleus.    
 
 
 
Figure 4-3: Methodology for differentiating human iPSCs into endothelial cells. Adapted from 
Patsch et al. [259].  
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To differentiate human iPSCs from PBMCs into endothelial cells we attempted several 
strategies. In one, we used the previously published method by Patsch et al. illustrated in Figure 
4-3 [259]. On day 0, human iPSCs were seeded on Matrigel and cultured in mTeSR1 medium. 
One day later, the media was changed to the Priming Medium described in more detail in the 
Methods. After three days of priming, iPS cells were induced for their differentiation into 
endothelial cells by the addition of VEGF and forskolin. Six days after priming and their 
differentiation, the endothelial cells were sorted using magnetic beads for CD31 and plated in 
0.05% gelatin coated plates to promote their growth and confluency. Visually, these iPSC-
derived cells failed to acquire the typical cobblestone appearance of endothelial cells. Thus, to 
examine the differentiation of human iPSCs into endothelial cells we used flow cytometry to 
measure the expression of CD31 and VE-Cadherin in these cells and in human aortic endothelial 
cells as positive controls. Using the gating strategy shown in Figure 4-4A, we found that in this 
colony of human iPSCs the differentiated cells expressed 0.4% of CD31 and 8.8% of VE-
Cadherin compared to the HAECs which expressed 99.6% and 58.6% of these markers 
respectively (Figure 4-4B-C). Given the lack of the characteristic cell morphology and the lack 
of CD31 and VE-Cadherin, which are typical markers of endothelial cells, we concluded that this 
protocol was not successful.  
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Figure 4-4: Characterization of human iPSCs subjected to differentiation into endothelial cells. 
Human iPSCs were subjected to differentiation into endothelial cells by BMP4 and GSK3 inhibition to 
commit these to a mesodermal fate and subsequently exposed these to VEGF and forskolin for their 
differentiation. Flow cytometry was used to characterized the differentiated cells. A. Flow cytometry dot 
plots are shown for live cells and single cells. B. Dot plots showing the expression of CD31 and (C) VE-
Cadherin on human aortic endothelial cells and our iPSC-derived cells.    
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Discussion  
The major findings in the experiments described in this chapter is that monocytes cultured with 
endothelial cells undergoing 10% stretch can promote T cell proliferation to a much greater 
extent than T cells cultured with monocytes exposed to endothelial cells undergoing 5% stretch. 
A conclusion to be drawn from these experiments is that increased endothelial stretch can 
convey to monocytes an ability to elicit an autoimmune-like response via T cell activation. In my 
prior experiments, I showed that monocyte activation involved STAT3 phosphorylation and the 
production of hydrogen peroxide and IL-6. It is interesting to speculate that these factors 
released by endothelial cells undergoing stretch arm monocytes to have this immunogenic 
property.  
A caveat of my initial experiments is that the endothelial cells were derived from different humans 
than were the monocytes and T cells. It is therefore possible that endothelial antigens released 
in response to 10% stretch from the different host could be presented by the monocytes from 
the other host to T cells and drive the proliferation observed in Figure 4-1. To avoid this, I sought 
to develop a system in which autologous T cells, endothelial cells and monocytes were used. In 
order to do this, we attempted to create iPSCs from freshly isolated PMBCs of our monocyte 
donors. A second goal was to successfully differentiate these into endothelial cells. Thus, we 
had two major hurdles to overcome in this effort. In initial experiments, I employed 
electroporation of AMAXA nucleofactor II® to introduce the transcription factor Klf4, Oct4, Sox2 
and c-Myc. This approach proved toxic to our PMBCs and did not yield iPSCs. As our second 
approach, I employed the Sendai virus approach to introduce these transcription factors as 
described by Tancos et al. [258]. This successfully yielded colonies of iPSCs as characterized 
by their appearance and their expression of Tra160 in the formed colonies (Figure 4-2).  
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Following the development of iPSCs, a second goal was to successfully induce these to become 
endothelial cells. To accomplish this, I used an approach described by Patsch et al. [259] in 
which iPSCs were exposed initially to BMP4 and GSK3 inhibition to commit these to a 
mesodermal fate and subsequently exposed these to VEGF and forskolin for their differentiation. 
This yielded a transformation of the iPSCs; however, they did not assume the cobblestone 
appearance of endothelial cells or express CD31 and VE-Cadherin, despite multiple attempts.     
It is uncertain why I was not able to successfully differentiate iPSCs into endothelial cells. Even 
Patsch et al. found that only 62 to 89% of iPSCs became endothelial cells [259]. These 
investigators also noted the presence of smooth muscle contaminating cells after their 
endothelial differentiation. It is possible that another source of iPSCs such as fibroblast or B cells 
would have yielded a higher population of endothelial cells. Others have used endothelial cells 
differentiated from PBMC-derived iPSCs, however, these are notoriously contaminated by 
fibroblast and do not yield enough numbers to perform experiments such as mine. After several 
approaches to produce iPSCs to successfully produce endothelial cells failed, we decided that 
this was not a valid experimental approach and decided to abandon it. 
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Chapter V 
Conclusions and Future Directions 
Synopsis  
Hypertension and main observations in thesis  
In the past several years, hypertension has been ranked as the leading risk factor for global 
burden of disease in both developed and underdeveloped countries [213]. According to the new 
guidelines, approximately 46% of the population in United States has hypertension and the 
occurrence of this disease increases with age. Hypertension is a major source of morbidity and 
mortality and promotes atherosclerosis, renal disease, stroke and heart failure [125]. In the past 
10 years, emerging evidence has supported a role of immune activation in hypertension. For 
several decades, the infiltration of T cells, B cells, monocytes and DCs into organs such as the 
kidney and the vasculature has been observed in both experimental models and humans with 
hypertension. Data in the last few years have supported the idea that these immune cells 
enhance blood pressure elevation and contribute to the end-organ damage associated with 
hypertension [137]. Until now, it has been unclear what factors present in the hypertensive milieu 
activate immune cells. Research from our laboratory and others have helped to uncover some 
of the factors involved in the immune activation during hypertension. DCs become activated in 
hypertension and we found that IsoLG-adducted proteins formed in these cells act as neo-
antigens and can promote T cell proliferation and activation [139]. More recently, we found that 
excess sodium, which accumulates in the interstitium and tissues, activates DCs to produce IL-
1β and promote T cell production of IL-17A [149]. In this dissertation, I found a new mechanism 
in which immune cells can become activated and some of the factors that promote this process. 
I made the following key observations: 
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1. Endothelial mechanical stretch, which is increased in  hypertension, activates and 
transforms adjacent human monocytes into the intermediate and CD209 cell phenotypes.  
2. This mechanism involves the activation of STAT3 within monocytes. STAT3 is essential 
for FLT-3-dependent DC development and acts as a transcription factor, inducing 
expression of cytokines that produce a pro-inflammatory response and can skew T cells 
toward an inflammatory phenotype.  
3. Other factors released from the endothelium undergoing stretch that could cross talk with 
monocytes and promote this process include ROS, in particular hydrogen peroxide, and 
IL-6. Further, we found that NO has an inhibitory effect on monocyte transformation in 
keeping with the concept that there is loss of NO bioavailability in hypertension. 
My studies not only used a unique cell culture system, but also extended findings from this 
system to the in vivo situation. One model involved the use of experimental mice exposed to 
Ang II-induced hypertension and we found that immune cells such as macrophages, DCs and 
monocytes infiltrate tissues such as kidney and aorta and that these have high levels of STAT3 
phosphorylation. In addition, we studied the transformation of the monocyte phenotype in a 
relatively large population of humans with hypertension and found there is a higher proportion 
of circulating pro-inflammatory intermediate monocytes as hypertension severity increases and 
that this population has the highest activation of STAT3. Therefore, the findings I initially 
observed in the monocyte-endothelial cell culture likely are relevant to experimental and human 
hypertension.   
Future directions  
The factors promoting monocyte activation and transformation in response to vascular stretch 
likely occur in concert with other factors encountered in hypertension including increased 
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sodium, catecholamines, and prostaglandins. These might all be part of the microenvironment 
in vessels undergoing stretch during hypertension. Future studies could address how these 
might work together in promoting monocyte activation and transformation during altered 
endothelial stretch. For example, one might increase sodium concentrations or add 
catetcholamines in the monocytes/T cell co-culture system I employed. Adding these factors 
together could mimic the in vivo setting and give insight into potential future therapeutic 
approaches. Further, future studies should focus on characterizing the three cell phenotypes 
that were the most strikingly altered by endothelial stretch and hypertension including the 
intermediate and non-classical monocytes as well as the CD209 population. For example, it 
would be important to determine if these cells have differences in their ability to produce 
inflammatory cytokines, or their ability to drive T cell activation and proliferation.  It would be 
important to identify which of these cell populations have the highest accumulation of the IsoLG-
adducts, which we have shown can induce T cell proliferation.  
To further characterize the intermediate monocytes and the CD209 cells that transform in 
response to endothelial stretch, it would be valuable to perform RNA sequencing on these to 
identify new genes associated with hypertension and vascular stretch. Another method we could 
use to characterize these would be to use Mass cytometry or CyTOF where we would label 
antibodies with heavy metal ion tags and perform analysis of multiple antibodies (approximately 
23) in order to detect the upregulation or downregulation of different proteins. With regard to 
RNA sequencing, recent studies from Villani et al. describe a new DC (AXL+SIGLEC6+) and 
monocyte population (Mon4) in humans [260]. The origin of these new DC and monocyte cell 
types and their role in hypertension is not known. In preliminary studies, I have shown that there 
is an increase in the DCs AXL+SIGLEC6+ in response to 10% endothelial stretch. Future studies 
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should consider further characterizing these populations and determining if they altered by 
increased endothelial stretch or in hypertension.  
Another mechanical force that the endothelium is exposed to is shear stress, which is the 
tangential drag of blood over the surface of the endothelium. In the clinical setting, 
atherosclerotic plaques develop preferentially at the arterial branches and curvature, which are 
regions of disturbed flow and shear stress. Similar to mechanical stretch, shear stress is 
important for promoting endothelial cell survival, leukocyte transmigration and the homeostasis 
of the vessel. There are various blood flow patterns that depart from the unidirectional laminar 
shear stress and these include flow reversal and turbulence [261].  Moderate unidirectional 
laminar flow is atheroprotective and maintains endothelial cell functionality (15 to 20 dynes/cm2). 
Low levels of laminar flow and oscillatory shear stress promote endothelial activation, ROS 
formation and inflammation. Endothelial cells treated with physiological levels of unidirectional 
flow have reduced VCAM-1 and E-selectin [262] as well as suppressed expression of IL-1β and 
TNF [263]. Further, laminar flow stimulates eNOS expression via Akt through the 
phosphorylation of Ser1177 [264]. Low shear stress and oscillatory shear stress lead to  loss of 
these beneficial effects and thus could interact with the increased mechanical stretch in the 
vessels that occurs in response to hypertension. In our studies, we did not address the potential 
effects of shear stress on the stretched endothelium. Future studies could address both 
mechanical forces on the endothelium and characterize the effects on the activation of the 
monocytes making this a more physiologically relevant model. Our in vivo studies likely 
encompass alterations of shear flow and stretch associated with hypertension.  
In Chapter II, we sought to determine if monocytes are mechanosensitive and can respond to 
stretch alone without the presence of endothelial cells. However, we did not observe monocyte 
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transformation or activation in response to stretch alone and this resulted in a vast cell death. 
We tested monocyte adhesion and transformation when seeded on RGD- or collagen I-coated 
plates, but we were not able to replicate the findings of when endothelial cells were present. 
Endothelial cells could be releasing specific factors that promote monocyte survival, but we 
cannot completely exclude the possibility that these monocytes have mechanoreceptors that 
respond to endothelial cell adhesion. Monocytes adhered to the endothelial surface might be 
transduced differently than monocytes adhered to artificial surfaces. As an example, I found that 
endothelial cells exposed to 10% stretch had high levels of ICAM-1. In future studies, one could 
examine if ICAM-1-coated plates might be able to transduce monocytes for their transformation 
and activation.   
We found two cell populations that were consistently increased in response to 10% endothelial 
stretch including the intermediate monocytes and the CD209 cells. Both of these were inhibited 
by STAT3 inhibition, but scavenging of hydrogen peroxide and IL-6 only prevented intermediate 
monocyte transformation and not the CD209 population. However, addition of NO donor 
prevented the transformation of both the intermediate monocytes and the CD209 population. It 
is interesting to speculate that these subsets might respond differently to NO, IL-6 and hydrogen 
peroxide. The CD209 cells had high accumulation of IsoLG-adducts and this could be mediated 
specifically by hydrogen peroxide. Formation of IsoLG-adducts within these cells might be 
promoting the transformation into the CD209 phenotype. In vivo, monocytes undergoing 
transmigration are in intimate contact with the endothelium-derived NO. This direct interaction 
with NO likely will have effects on the monocyte biology. 
Nitric oxide signals through multiple mechanisms, but the predominant pathway involves the 
formation of cyclic guanosine monophosphate (cGMP) via the enzyme guanylyl cyclase. This 
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leads to activation of cGMP-dependent protein kinase (PKG) [265]. PKG phosphorylates multiple 
downstream targets including RhoA, the myosin-binding subunit, thrombin receptor, and others 
[266, 267]. A readout for PKG function is the actin binding protein, vasodilator-stimulated 
phosphoprotein (VASP). In preliminary studies, we have shown phosphorylated VASP in 
monocytes exposed to endothelial cells undergoing stretch. This indicates that NO in our system 
might be signaling through cGMP. NO can signal through other mechanisms than cGMP. For 
example NO, via formation of peroxynitrite via reaction with superoxide, can form nitrotyrosines, 
which can reduce the ability of tyrosine to be phosphorylated and this can dramatically alter cell 
signaling [268]. Nitric oxide can also bind to other heme proteins including those in the 
mitochondria and modulate mitochondrial respiration [269]. NO can also modulate s-
glutathionylation by forming peroxynitrite [270]. Thus, future studies can focus on which of these 
pathways are most important in modulating monocyte phenotype. For example, it would be 
interesting to determine if cGMP is important in modulating monocyte phenotype. However, 
further studies characterizing this need to be performed in order to determine how NO talks to 
monocytes. In addition to nitric oxide, it would be important to further characterize the signals 
released by the endothelium in response to hydrogen peroxide on monocytes. Hydrogen 
peroxide is a relatively stable ROS that can promote the activation of principle signaling 
cascades including ERK, JNK, p38, MAPK and PI3K/Akt [271]. Thus, future studies on 
determining which of these signaling cascades is involved would deem a valuable addition to 
this mechanism.  
We found that IL-6 plays an important role in the transformation of monocytes into the 
intermediate phenotype. IL-6 has been shown to both stimulate STAT3 activation and to be 
produced in response to STAT3 in a feed-forward fashion [231]. STAT activation occurs by 
129 
 
phosphorylation of the SH2 domain and C-terminal transactivation domain [STAT1 (Y701), 
STAT2 (Y690) and STAT3 (Y705)]. Upon cytokine stimulation, JAKs are recruited to the receptor 
and becomes phosphorylated and STATs are recruited to the receptor via their SH2 domain and 
are phosphorylated by JAKs on the respective residues [190]. This phosphorylation enables 
STATs to either homodimerize or heterodimerize via their SH2 domains and translocate to the 
nucleus and interact with DNA motifs to promote gene transcription [191]. However, STAT3 is 
also activated via other mechanisms that are JAK-independent. Other intracellular activators of 
STAT3 include epidermal growth factor receptor (EGFR), Src and ERK [272]. STAT3 is also 
activated through serine 727 phosphorylation. This phosphorylation occurs in response to 
protein kinase C, CDK5 and mitogen-activated protein kinases. Another mechanism of STAT3 
activation is reversible acetylation of STAT3 by histone acetyltransferase on a single lysine 
residue (Lys 685) [273]. This acetylated STAT3 enhances the stability of STAT3 dimers, which 
is required for DNA-binding and transcriptional activity. In addition, our laboratory has defined a 
new mechanism by which STAT3 can be activated in the nucleus by PKM2 [228]. In preliminary 
studies, we found that inhibition of JAK using tofacitinib drug on the monocyte-endothelial cell 
culture undergoing stretch did not prevent transformation and activation of STAT3. Further 
studies could be performed to confirm if activation of STAT3 is JAK-independent and to define 
other mechanism of STAT3 activation in monocytes exposed to endothelial cells undergoing 
stretch. 
Conclusion 
Taken together, the studies performed in this thesis have defined a new mechanism by which 
monocytes and other immune cells become activated in hypertension. The mechanical stretch 
of vessels that occurs in response to increased blood pressure releases factors including IL-6, 
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hydrogen peroxide and nitric oxide that modulate the phenotype of nearby monocytes. We have 
shown that this process of monocyte activation occurs in part via STAT3 and secondary signaling 
events mentioned above. Our current study provides a previously unrecognized link between 
mechanical forces affecting the endothelium and activation of monocytes. This allows new 
insight into how the immune system can be activated in hypertension and for the first time 
implicates intermediate monocytes as potentially important in this disease. Thus, altered 
endothelial mechanical forces could have important effects on immune cell function, leading to 
end organ damage and worsening hypertension.  
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